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SUMMARY 
New high throughput technologies have made it possible to screen complete cancer genomes for 
identification of mutations associated to cancer. These analyses have pointed out that there are 
only a few commonly mutated genes and many infrequently mutated genes, highlighting the 
heterogeneity in the genes that cause cancer. The validation of the possible role for each of these 
genes in cancer is a difficult task, considering the existence of driver mutations and many 
“passenger” mutations in cancer genomes. To overcome these difficulties, comparative 
genomics has proved to be a useful tool when looking for candidate cancer genes that are 
mutated in tumors that arise in model mice. Transposons represent important genetic tools for 
functional genomic screening and recently the Sleeping Beauty transposon system, which can 
act as an insertional mutagen, has been developed to mutate and identify novel cancer genes in 
transgenic mice. The major aim of this project is to identify novel cancer genes involved in the 
development of two tumor types that are incompletely characterized at genetic level:  non-
melanoma skin cancer and breast cancer malignancies. For this purpose, we have used the 
Sleeping Beauty transposon system to identify somatic mutations associated with skin and 
breast cancers.  
We generated transgenic mice carrying multiple copies of the mutagenic transposon T2Onc2 
and expressing the SB11 transposase specifically in tissues where keratin K5 is expressed 
(SB/T2 mice). When these mice were subjected to several skin carcinogenesis regimes, they 
developed more tumors than mice lacking active transposons in the skin. Moreover, these 
tumors showed worse histological characteristics than those obtained in control mice, 
presumably as a result of the mutagenic effect of transposon mobilization. Genetic analysis of 
the transposon insertion sites in the tumors identified 126 genes recurrently mutated in different 
tumor samples, which may represent candidate cancer genes. When the expression levels of a 
subset of the most transposon-mutated genes were analyzed in skin human samples, we detected 
alterations in the expression levels of some of these genes in human tumors. Our results show 
that inactivating mutations in Notch1, Nsd1 among others, may have an important role in skin 
carcinogenesis. We also generated heterozygous p53+/- mice bearing multiple copies of the 
T2Onc2 transposon and the SB11 transposase. These mice developed mammary gland 
carcinomas with higher incidence and shorter latency period than control mice that did not 
undergo transposition. High throughput sequencing analysis of the transposon insertion sites 
within the tumors identified 53 candidate cancer genes that were commonly mutated in different 
transposon/transposase tumor samples. Immunohistrochemical analyses revealed that NF1 and 
RASA1 (two of the most frequently transposon-mutated genes in our animal model) were 
expressed at a reduced level in human breast tumor samples. Therefore, this study shows that 
NF1 and RASA1 may be important for breast cancer development. 
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RESUMEN 
Las nuevas técnicas de secuenciación masiva han posibilitado el análisis genómico de tumores 
para identificar mutaciones asociadas a cáncer. Estos análisis han averiguado que hay un 
número pequeño de genes mutados frecuentemente y gran número de genes mutados 
infrecuentemente, poniendo de manifiesto la heterogeneidad de los genes que causan cáncer. La 
validación del posible papel de cada uno de estos genes en cáncer es una tarea difícil, ya que 
hay mutaciones conductoras y pasajeras en los genomas de cáncer. Para vencer estas 
dificultades, la genómica comparativa ha demostrado ser una herramienta muy útil para la 
búsqueda de genes importantes en el desarrollo del cáncer, a través de la determinación de los 
genes mutados en tumores originados en modelos de ratón. Por otra parte, los transposones 
representan herramientas genéticas muy importantes para el análisis genómico; recientemente se 
ha desarrollado el sistema de transposición “Sleeping Beauty” (SB) para mutar e identificar 
nuevos genes implicados en cáncer en modelos animales. Finalmente, tanto el cáncer de piel (no 
melanoma) como el cáncer de mama están incompletamente caracterizados a nivel genético. El 
principal objetivo de este trabajo es la identificación de mutaciones somáticas asociadas a estos 
dos tipos de cáncer mediante el uso del sistema de transposición SB en ratones transgénicos. 
Hemos generado ratones transgénicos portadores de múltiples copias de un transposón 
mutagénico y de la transposasa necesaria para su movilización específicamente en tejidos donde 
se expresa la queratina K5 (ratones SB/T2). Cuando estos ratones fueron sometidos a varios 
protocolos de carcinogénesis de piel, desarrollaron más tumores que ratones sin transposones 
activos en piel. Además, estos tumores presentaron peores características histopatológicas que 
los obtenidos en animales control. El análisis de los sitios de inserción del transposón en los 
tumores identificó 126 genes mutados de manera recurrente. Estos genes son candidatos a 
desempeñar un papel importante en el desarrollo tumoral. Nuestros resultados muestran que 
mutaciones que inactivan NOTCH1 y NSD1, entre otros genes, puede ser importante para la 
carcinogénesis de piel. 
También hemos generado ratones SB/T2 en un fondo genético heterocigoto para Trp53. Estos 
ratones desarrollaron carcinomas de glándula mamaria con mayor incidencia y menor latencia 
que ratones sin transposición activa. El análisis de los sitios de inserción en los tumores 
mamarios por secuenciación masiva identificó 53 genes candidatos de cáncer que estaban 
mutados de manera recurrente en diferentes tumores. Estudios inmunohistoquímicos pusieron 
de manifiesto que dos de los genes más mutados por el transposón en nuestro modelo animal 
(en concreto NF1 y RASA1) se expresan a menor nivel en muestras humanas de cáncer de 
mama que en tejido no tumoral. Estos resultados indican que NF1 y RASA1 pueden ser 
importantes para el desarrollo del cáncer de mama. 
  12 
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 1. NON-MELANOMA SKIN CANCER 
1.1 The biology of non-melanoma skin cancer 
 
The skin epidermis is a stratified epithelium composed principally of keratinocytes, whose 
proliferation and differentiation must be tightly regulated and coordinated in order to maintain 
skin homeostasis and determine effective response to injury. Failures in the regulation of these 
processes precipitate skin disorders, such as skin cancer. Cells that reside at the base of the 
epidermis are called basal keratinocytes and are less differentiated and possess proliferative 
potential. As basal keratinocytes divide, their progeny detach from the underlying basal lamina 
and migrate vertically. Thus, they become postmitotic and committed to an irreversible 
differentiation program, culminating in enucleation, internal degradation and transformation 
into squames that constitute the most superficial layer or stratum corneum. Since the outermost 
squames are continuously shed from the surface of the skin, the basal cells of the epidermis 
maintain a steady proliferative rate to compensate from this loss (Figure 1) 
 
Figure 1. Epidermal stem cells are located in the basal layer of the epidermis. These stem cells 
give rise to transient amplifying cells that migrate to the surface undergoing a differentiation 
process 
 
The process of skin tumor formation follows 3 steps: tumor initiation, tumor promotion and 
tumor progression. Tumor initiation involves crucial gene mutations in proto-oncogenes and/or 
tumor suppressor genes in skin cells. Tumor promotion consists of clonal expansion of these 
cells that will give rise to a benign tumor. Tumor progression involves the conversion of the 
benign tumor into an invasive and potentially metastatic malignant tumor (Figure 1). 
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Figure 2. Schematic representation of skin tumor development 
 
Non-melanoma skin cancer (NMSC) is the most common form of human cancer, with incidence 
rates dramatically increasing over the last decade, probably as a result of increased sun exposure 
and the depletion of the ozone layer. The two more frequent types of cancer in NMSC are basal 
cell carcinoma (BCC) and squamous cell carcinoma (SCC). Approximately, 80% of the NMSC 
cancers are BCCs and 20% correspond to SCCs. BCCs are keratinocyte tumors characterized by 
local invasion and contiguous spread that cause tissue destruction, but rarely metastasize. Most 
of BCCs occur sporadically, but they also develop as part of heritable syndromes like Gorlin 
syndrome, linked to mutations in the PTCH1 gene (90). They classically appear as lesions on 
the sun-exposed areas of skin, being much more frequent in fair-skinned individuals of 
European ancestry. Histologically, BCC cells resemble to basal cells of the interfollicular 
epidermis, the hair follicle or the sebaceous gland and it is thought that BCC arise from the 
basal cells specifically of the hair follicle. SCCs tumors also arise from cutaneous keratinocytes. 
However, they are biologically aggressive tumors that after local invasion and tissue destruction 
may metastasize (1-12.5%) to lymph nodes and can cause death if not treated properly. While 
BCCs are believed to develop de novo, SCCs development follows a mutational multistep 
process, characterized by well-defined precancerous skin lesions that can lead to actinic 
keratosis (AK) or kerathocantomas (KA). AKs consist of a focal dysplasia of epidermal 
keratinocytes that is followed by carcinoma in situ or Bowen’s disease, that represents a 
preinvasive stage of skin SCCs. KAs are benign cutaneous squamous neoplasias arising 
preferentially on sun-exposed skin that have been also classified as premalignant SCC lesions. 
The incidence of SCC is greatly increased in immunosuppressed patients and human papilloma 
virus (HPV) infected individuals. A number of heritable conditions are associated with an 
increased risk of SCC, including xeroderma pigmentosum, recessive dystrophic epidermolysis 
bullosa and dyskeratosis congenita but contrary to what happens to BCC, the genetic defects in 
these syndromes are not specific for SCC. They are believed to arise as a secondary result of 
increased epidermal mutagenesis. 
Although some specific therapies have been developed to treat NMSC, surgery still remains as 
the primary therapeutic modality.  
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1.2 Mutated genes and deregulated pathways in non melanoma skin cancer  
 
Cumulative exposure to ultraviolet radiation (UV) is considered as the most common risk factor 
of NMSC, but other factors such as immunological status, genetic predisposition and infection 
by HPV may also be involved. UV light induces DNA damage in keratinocytes, and it can 
mutate genes essential for control and surveillance in the skin epidermis. Damaged DNA cells 
are repaired and if this it not possible, they are eliminated by apoptosis (sunburn cells), a 
process that occurs under the control of the P53 gene. P53 gene mutations by UV radiation 
leads to genome-wide instability, chromosomal amplifications and wide allelic imbalance; being 
the starting point of SCCs and some BCCs. Several other gene pathways have been correlated to 
NMSC development and progression. So, mutations in several genes of the SHH pathway are 
known to be a main cause of BCCs; the Ras pathway is altered in SCCs and BCCs; and 
deregulation of MYC, CDKN2A and NF-κB  has also been reported in this type of cancers.  
1.2.1 P53 mutations in NMSC 
The TP53 tumor suppressor gene encodes the P53 nuclear transcription factor that plays a 
central role in the decision between DNA repair or apoptosis following UV radiation-mediated 
damage. It arrests cell division at G1 phase to allow DNA repair by promoting p21-mediated 
inhibition of cyclin-dependent kinases complexes. Cell apoptosis is induced through p53-
induced expression of genes like NOXA, PUMA or BAX if the genomic damage cannot be 
repaired (Figure 3). Additionally, an antioxidant function for this gene has also been proposed, 
protecting the cell against oxidative stress 
 
Figure 3. Schematic representation of the P53-mediated response after DNA damage. 
Activation of p53 results in transcriptional activation of a variety of genes including, NOXA, 
PUMA, BAX and APAF-1 that contribute to apoptosis. (Modified from Crighton (36)) 
 
Mutational inactivation of the P53 gene allows damaged or incompletely repaired cells to 
progress through the cell cycle and to pass their damaged genomes to daughter cells. Mutations 
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in P53 are considered to be the earliest event in NMSC and 50% of these cancers are p53-
mutated. Many P53 mutations found in these tumors consist of C to T or CC to TT transitions, 
consistent with an UV radiation signature (23). These mutations do not appear at random, 
showing a pattern of hot spots different from that of internal malignancies (222). These data 
support the role of UV light as the main cause for P53 gene inactivation in NMSC. Although 
mutations in P53 have been found in both BCC and SCC, it has been proposed an important 
role of P53 mutation in the pathogenesis of SCCs. According to experimental data, more than 
70% of preinvasive SCCs display p53 mutations (28), implicating that p53 mutation is an early 
event in SCC development.  
However, it has been found that Trp53 knockout mice display a surprising resistance to skin 
carcinogenesis induced by overexpression of certain oncogenes (67). In addition, results of 
experimental approaches to alter P53 function vary according to genetic deletion versus 
overexpression of well-characterized mutant P53 proteins. Thus, it is still necessary to perform 
further studies to understand the functional consequence of p53 mutations in NMSC 
development. 
 
Figure 4.Schematic representation of UV-induced skin carcinogenesis. Both UV-B and UV-A can 
contribute to tumor development.by direcly inducing DNA damage, such as P53 mutations or 
indirectly generating genomic instability. (Modified from Boukamp,(24)) CIS (Carcinoma in situ) 
 
 
1.2.2 Role of the Hedgehog signaling pathway in NMSC 
The Hedgehog (HH) signaling pathway is involved in the regulation of embryo growth and 
patterning in mammalian development, and has also been implicated in the maintenance of stem 
or progenitor cells in many adult tissues. Mutations in components of this pathway are involved 
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in the development of a broad list of cancers including medulloblastoma, breast carcinoma, 
meningioma, colon carcinoma, pancreatic and oesophageal adenocarcinomas and small cell lung 
cancer.  
The PTCH1 gene encodes a transmembrane protein that acts as a receptor for the Hedgehog 
extracellular ligands, being sonic hedgehog (SHH) the best characterized ligand. The SHH 
ligand binds to PTCH1 protein to activate the pathway. In the absence of SHH binding, PTCH1 
holds the smoothened (SMO) protein, a G protein-coupled receptor, in an inactive state, 
inhibiting signaling to downstream genes. When SHH ligand binds to PTCH1, inhibition of 
SMO is released and the signal is transduced through a series of interacting proteins including 
suppressor of fused (SUFU), leading to the activation of the transcription factors GLI1, GLI2 
and GLI3. Their target genes include cell cycle regulators, WNT, TGFB and PTCH1 and GLI1. 
The upregulation of PTCH1 provides negative feedback and that of GLI1 provides positive 
feedback to the HH signaling pathway (Figure 5).  
 
Figure 5. Schematic representation of SHH signaling pathway.  When SHH ligand binds to 
PTCH, SMO becomes active and initates a signaling cascade that results in the activation of GLI 
transcription factors. GLI proteins interact in a complex that includes Fused (FU) and 
suppressor of FU (SUFU). (Modified from Pasca di Maliano and Hebrok,(135)) 
 
The Gorlin syndrome is an autosomal dominant inherited syndrome in which patients have a 
marked susceptibility to develop BCCs (70). Family-based linkage studies of kindreds with 
Gorlin syndrome resulted in the identification of mutations in the PTCH1 gene. After that, 
PTCH1 mutations were also found in sporadic BCCs (9). These findings linked this pathway to 
BCC development and progression. Approximately, 70% of sporadic BCCs have identifiable 
mutations in at least one allele of PTCH1. Many of these mutations are consistent with an UV 
signature, indicating an UV-radiation origin. Another 10% of BCCs have activating mutations 
in SMO gene (208). A smaller number of BCCs have mutations in PTCH2, the PTCH1 
homologue and in SUFU. In addition, It has been found that BCCs overexpress GLI1 and GLI2, 
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indicating that the HH pathway is constitutively active in BCC (10),(148). However, mutations 
in PTCH1, SMO or SUFU have not been found in all BCCs, so it seems likely that other genes 
of the HH pathway maybe mutated in some BCC. Although several experiments have been done 
to determine genome-wide expression differences in BCC tumor samples versus control skin, 
there is only a limited understanding of which downstream expression changes are actually 
crucial for HH-induced BCC carcinogenesis. 
Possible downstream mediators of BCC carcinogenesis from HH signaling activation include 
up-regulation of apopotosis inhibitors, as BCL-2 (147) and cFlip (58);  downregulation of  
apoptosis inducers as the tumor necrosis factor superfamily member FAS (110) and BMI1 
(149), as well as up-regulation of PDGFR (207). Other downstream HH components are the 
transcription factors FOXM1 and FOXE. Their overexpression leads to activation of the cell 
cycle and proliferation. Overexpression of FOXM1 has been found in BCC tumors (182). 
However, it is still unclear which downstream changes are essential for BCC tumorigenesis. 
In addition, other signaling pathways are likely to be involved through their interaction with the 
HH pathway, such as those pathways regulated by EGFR, PI3K/AKT and PKC. Experimental 
data revealed that EGFR signaling through RAS/RAF/MEK/ERK induces Jun/AP1 activation 
that acts synergistically with activated forms of GLI1 and GLI2 in epithelial oncogenic 
transformation (158). Data also show that PI3K and AKT activities are essential for Gli-SHH 
signaling and that PI3K/AKT signaling potentiates GLI1 activation induced by low levels of 
SHH (150). It has also been proposed that PI3K/AKT can stabilize GLI2 through inhibition of 
PKA. These data determine a synergistic relation between the PI3K/AKT and HH pathways. 
1.2.3. Wnt signaling  
A recent study presents convincing evidence regarding the role of Wnt signaling in BCC 
carcinogenesis, being downstream of HH signaling in these tumors (211). These authors have 
reported the need of canonical Wnt/β-catenin signaling for HH-driven tumorigenesis, as Wnt 
pathway inhibition prevented the formation of tumoral lesions in animal models without 
affecting HH signaling. 
1.2.4. Cell cycle inhibitors 
The CDKN2A locus encodes p16INK4a and p14ARF cell cycle inhibitors. p16INK4  inhibits cell cycle 
progression in the G1 phase by binding and inhibiting CDK4/6 kinases, that phosphorylate the 
RB protein. Upon RB phosphorylation, activated E2F promotes induction of p14ARF, which 
sequesters MDM2 preventing degradation of p53. Loss of these proteins leads to the promotion 
of cell division. Mutations in the CDKN2A gene have been found in sporadic SCC (154) and 
overexpression of CDK4 and oncogenic RAS is sufficient to induce human SCCs (105). 
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1.2.5. The RAS proto-oncogene  
The Ras gene family encode Ras GTPase proteins that regulate proliferation, angiogenesis, 
apoptosis and cellular morphology and are considered to be among  the most widely altered 
oncoproteins in human neoplasia. The human H-RAS proto-oncogene is the most frequently 
activated member of the Ras family in NMSC. Consequently, activation of Ras/Raf signaling 
has been implicated in both BCCs and SCCs and cDNA studies have shown an induction of 
known Ras target genes in human SCC patient tissue versus matched normal skin samples. 
However, only an overall H-ras mutation frequency of 10/20% has been found in NMSC tumors 
(114), (29).  
1.2.6. The NF-κB pathway 
NF-κB proteins are conserved transcription factors implicated in regulating inflammation, 
morphogenesis, apoptosis, differentiation and proliferation. In contrast to its oncogenic role in 
other settings, NF-κB acts as an important proliferative safeguard in stratified epithelium. Its 
blockade is related to hyper-proliferation in both murine SCC (188) and human epidermis (160). 
Additionally, it has been shown that NF-κB blockade and expression of oncogenic Ras 
produced a SCC-like neoplasia in normal human epidermal cells (38).  
 
1.3. Mouse models used for the study of human skin cancer  
1.3.1. The multistep chemical carcinogenesis skin tumor model in mice 
The multistage skin carcinogenesis protocol using DMBA/TPA has been widely used to address 
important skin carcinogenesis process questions (141). It involves treatment of the dorsal skin 
of mice with a single dose of the mutagenic agent 7,12-dimethylbenz[a]anthracene (DMBA), 
followed by weekly applications of the hyperplasic agent 12-O-tetradecanoylphorbol-13-acetate 
(TPA). DMBA causes mutations in the H-ras oncogene (141), (12). TPA is a tumor promoter 
that activates PKC (186). Upon activation by TPA, PKC sets in motion pathways leading to the 
upregulation and activation of transcription factors such as c-fos and c-jun (AP1) that play an 
important role in initiating cell proliferation. During papilloma promotion chromosomal 
abnormalities are also frequent (4, 34). 
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Figure 6. Schematic representation of the DMBA/TPA protocol. DMBA causes intial mutations 
and TPA causes an hyperproliferation of the initially mutated cells that can lead to papilloma 
formation. Papillomas can then originate SCC-like tumors and metastasize 
 
This process gives rise to papillomas, which are benign neoplastic lesions consisting of 
hyperplastic keratinocytes and supporting stromal cells. Although many papillomas regress, a 
small percentage of papillomas progresses to malignant, invasive squamous cell carcinomas 
(73). Carcinomas invade through the basement membrane and are characterized by loss of 
differentiation, increased mitotic activity, and nuclear atypia. A small fraction of these 
carcinomas can metastasize to distant places.  
The conversion to carcinomas is characterized by loss of heterozigosity and mutation of p19/Arf 
and p16Ink4a or Trp53 (99), (94), and increases in mutant H-ras via gene amplification (26). In 
fact, reduction of Trp53 gene dosage enhances malignant progression of chemically induced 
skin tumors (93). These aggressive carcinomas also present inducted overexpression of Snail 
and Slug genes involved in epithelial mesenchymal transition (EMT) (22), (30). 
1.3.2. The Tg.AC transgenic mouse 
These mice represent an improvement to the DMBA/TPA protocol, since they do not need to be 
initiated. These mice carry a transgene consisting of an oncogenic H-ras coding region flanked 
in its 5’ region by a mouse ζ-globin promoter and in 3’ by an SV-40 polyadenylation sequence. 
Located on chromosome 11, the transgene is transcriptionally silent until activated by 
hyperproliferative stimuli, including TPA, UV light, or full thickness wounding. Expression of 
the transgene is an early event that drives cellular proliferation resulting in clonal expansion and 
tumor formation. When these mice are treated topically with TPA, they develop multiple 
papillomas and some of them can progress to malignant spindle or squamous cell carcinomas 
(107), (169) 
1.3.3. Mouse models of BCC carcinogenesis 
The DMBA/TPA and Tg.AC classical skin cancer models have been very useful to study genes 
related to SCC tumors, but these models are not able to produce BCC-like tumors. Therefore, 
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several mouse models were engineered carrying inactivating mutations in genes that belong to 
the HH signaling pathway.  
Ptch1+/- mice are prone to develop BCCs after receiving mutagenic ionizing or UV 
radiation(8),(120). Overexpression of SHH and active SMO, GLI1 or GLI2 genes promote 
development of BCC-like tumors (9), (134), (66). These experiments have highlighted the 
importance of alterations in the HH signaling in BCC development. Additionally, it has been 
seen that conditional Trp53 loss in K14 or K15-expressing keratinocytes markedly enhances 
HH-driven tumorigenesis in Ptch1 +/- mice (199), reinforcing the role of p53 in BCC 
carcinogenesis. Additionally, results of pharmacological interventions in the Ptch1+/- mouse 
seem to correlate well with the results of the same intervention in humans (180).   
 
2. BREAST CANCER 
2.1 The biology of breast cancer 
 
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death 
among women worldwide, accounting for 23% of the total new cancer cases. More than 1.4 
million new cases of breast cancer occurred among women worldwide in 2008 (25). The 
mammary gland consists of a branching ductal system that ends in terminal ducts with their 
associated acinar structures, termed the terminal ductal lobular units (TDLUs), together with 
interlobular fat and fibrous tissue. TDLUs comprise two types of epithelial cells: inner secretory 
luminal cells (ductal and alveolar subtypes) and outer contractive myoepithelial/basal cells. The 
stroma is composed of adypocites, fibroblasts and different immune cells.  
The initiation of breast cancer is caused by transforming events, including genetic and 
epigenetic changes in a single cell. Subsequent tumor progression is driven by the accumulation 
of additional genetic changes combined with clonal expansion and selection. The process 
involves hyperproliferation of ductal cells that will lead to ductal carcinoma in situ (DCIS) or 
lobular carcinoma in situ (LCIS), followed by evolution into an invasive carcinoma and 
metastasis. Transformation from carcinoma in situ to invasive carcinoma comprises the 
disappearance of the myoepithelial cell layer as an organized entity, so ductal cells from inside 
lobules or ducts can invade nearby breast tissue. Metastasis process involves spread of 
mammary gland tumor cells through blood and lymphatic vessels to distant organs, more 
frequently lungs, bones and liver (Figure 7) 
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Figure 7. Schematic representation of breast cancer progresión. Epigenetic and genetic 
changes and interactions with the microenvironment cause the transformation of normal 
breast epithelial cells to tumor cells that can lead to metastatis by extravasation to distant 
organs. (Modified from Polyak (137)) 
 
Five major molecular subtypes of ductal breast cancer have been determined by gene expression 
profiling of large sets of tumors: Luminal A, Luminal B, HER2+, Basal like (“triple negative”) 
and Claudin-low; each subtype has a different rate of incidence, survival and response to 
treatment (183). Luminal A represents the most frequent form of breast cancer and has the best 
prognosis, while the basal-like has the worst outcome being frequently associated with 
metastasis. They have been classified according to expression of progesterone receptor (PR), 
estrogen receptor (ER) and Erbb2 (HER2) expression status in the tumors (Figure 8) 
 
 
Figure 8. Molecular classification of breast tumors 
 
2.1.1. Keratin distribution in mammary cell lineages and mammary epithelial stem cells 
The mammary gland development is characterized by different keratin expression along the 
process. Each mammary cell lineage shows a specific keratin expression pattern. In adult tissue, 
luminal cells (ductal and alvelolar) express preferentially keratin 8 (K8) and keratin 18 (K18); 
and myoephitelial cells are characterized by expression of keratins K5 and K14. However, 
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between embryonic days E15.5 and E18.5 in the mouse, nearly all epithelial cells express both 
K5 and K14.(177)  Experiments in vitro have shown that this keratin expression pattern 
characteristic of mouse mammary cell lineage is also conserved in primary human mammary 
epithelial cells (177). The mammary epithelium suffers deep remodeling processes in each 
menstrual cycle and in pregnancy, lactation and involution. This has lead to the proposal of the 
existence of adult mammary epithelial stem cells. According to this, implantation experiments 
in the mouse have revealed the presence of progenitor cells that when transplanted into a mouse 
cleared fat pad can regenerate the mammary gland (102), (174), (161). Breast epithelial stem 
cells are bipotential stem cells able to self-renew and able to produce luminal and myoepitelial 
progenitors (Figure 9).  
 
Figure 9. Schematic representation of the epithelial cell hierarchy within the mammary gland. 
A stem cell divides to generate a bipotent progenitor that originates both luminal and 
myoepithelial progenitor; these differentiate into myoepithelial cells. Luminal progenitors 
differentiate into cells of ductal or alveolar lineales. (Modified from Macias (119)) 
 
Besides its normal function in tissue development, the importance of mammary epithelial stem 
cells has been addressed in the development of breast cancer. It has been proposed that breast 
stem cells would be the tumor-initiating cells since they exist quiescently over long periods of 
time and could, therefore, accumulate mutations over the life-span of an organism and give rise 
to tumors when stimulated to proliferate. In addition, it has been seen that around 40% of breast 
tumors recur 10 years after removal of the primary tumor. This could be due to the existence of 
cells with a long life span and self-renewal capacity, similar to stem cells behavior. 
2.2. Genes mutated in breast cancer 
 
Somatic breast cancer may arise from a combination of multiple acquired genetic events that 
include gain-of-function mutations in proto-oncogenes that stimulate cell growth, division and 
survival; and loss-of-function mutations in tumor suppressor genes that normally prevent 
abnormal cellular growth and promote DNA repair and cell cycle checkpoint activation. 
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Epigenetic changes also contribute to deregulate the expression of these genes. Only 25% of 
breast cancer cases are due to inherited gene mutations. 
Breast cancer genome analysis indicates that there are only a few genes that are frequently 
mutated but many that are infrequently mutated. These data provides an explanation for the 
observed breast cancer molecular heterogeneity. ERBB2, PI3KCA, MYC and CCND1 oncogenes 
are frequently deregulated in breast cancer. Among tumor suppressor genes, BRCA1, BRCA2, 
TP53 and PTEN are the most mutated genes. 
2.2.1. Role of oncogenes 
PI3KCA is the gene most mutated somatically in human breast cancer samples according to the 
Catalogue of Somatic Mutations in Cancer (COSMIC). Alterations in upstream components of 
the PI3K pathway, such as receptor tyrosine kinases, and downstream components, such as 
AKT, that regulate control of cell proliferation, cell survival and metabolism, are frequent in 
breast cancers. It has been proved that mutations in PI3KCA lead to a constitutive activation of 
AKT in human mammary gland epithelial cells (83). Direct evidence supporting a role for the 
AKT  family of genes in breast cancer has been also obtained  using transgenic mice carrying 
activating forms of this gene (82). 
ERBB2 (known also as HER2 or HER2/neu) is a member of the EGFR family of receptor 
tyrosine kinases (RTKs). ERBB2 expression levels are elevated in 20/30% of human breast 
cancers because of genomic amplification of the ERBB2 proto-oncogene (166). Overexpression 
of ERBB2 results in aggressive tumors, being frequent in human ductal carcinomas and rarely 
observed in benign breast hyperplasias. In addition, elevated expression of ERBB2 is usually 
associated to tamoxifen resistance of the primary tumor. Studies using transgenic mice carrying 
the Erbb2 gene under the transcriptional control of the MMTV promoter or of the  Erbb2 
promoter support the role of this gene in breast cancer (68), (6).  
MYC encodes a nuclear phosphoprotein involved in cellular proliferation, differentiation and 
apoptosis. It is amplified and overexpressed in 15-25% of breast tumors (126). Experiments 
using transgenic mice overexpressing Myc under MMTV or WAP promoters showed that these 
mice developed tumors, but since tumor incidence was low (108) and WAP-Myc animals 
required pregnancy to develop tumoral lesions (159), it was established that additional 
mutations in other oncogenes were necessary for the induction of carcinogenesis.  
CCND1 encodes the protein Cyclin D1, a cell cycle regulator that controls the progression from 
G1 to S phase. This protein is overexpressed in 40/50 % of invasive breast tumors and its gene 
is amplified in 10/20% of the cases (172). Lobular carcinoma universally overexpress Cyclin 
D1, while overexpression in ductal carcinoma appears to be restricted only to ER+ cases (178). 
Overexpression of this gene under the control of the MMTV promoter in transgenic mice 
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resulted in mammary adenocarcinomas.  Cyclin D1 overexpression is also essential for the 
development of mammary cancers induced by ErbB2 and Ras expression (214). 
2.2.2. Role of tumor suppressor genes 
P53 is the second most somatically mutated gene in human breast cancer samples according to 
COSMIC. It is estimated that 20 to 30% of breast  tumors carry mutations in P53 (76). Breast 
tumor progression seems to be associated with mutant P53, since a higher frequency of P53 
mutations is seen in patients with advanced disease. The role of P53 mutations in breast cancer 
is further supported by the fact that Li-Fraumeni syndrome patients, carrying germline P53 
mutations, are predisposed to develop breast cancer at a relatively early age (190) . 
PTEN antagonizes the PI3K pathway. Inherited mutations of PTEN, such as those in Cowden 
syndrome, increase the risk of breast cancer (127). In addition, loss of PTEN has been related to 
a worst outcome in breast cancer patients, correlating with metastasis and disease associated 
death (42). Conditional ablation of PTEN gene in the mammary epithelium in transgenic mice 
accelerated mammary tumor progression (156).  
The BRCA1 gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic 
instability, acting as a tumor suppressor. The encoded protein combines with other tumor 
suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein 
complex known as the BRCA1-associated genome surveillance complex (BASC). This protein 
plays a role in transcription, DNA repair of double-stranded breaks, and recombination (61). 
Linkage analysis of families with multiple cases of breast cancer linked BRCA1 to hereditary 
breast cancer. BRCA1 mutations account for 5% of all breast cancer cases occurring in women 
under 40 years but rises up to 90%  in  families with four or more cases of breast cancer (60). 
80% of the BRCA1 mutations result in abnormal truncation of the protein. BRCA2 functions are 
similar to those of BRCA1 and most of the mutations found in this gene also result in premature 
truncation of the protein. Although mutations in BRCA1 and BRCA2 genes are the most 
frequently identified causes in familial breast cancer, they are rarely found in sporadic cancer. 
Additional tumor suppressor genes such as RB, ATM and CHK2 have been also related to 
human breast cancer development. 
2.3. Transgenic mouse models used in breast cancer research 
 
Transgenic mice have been widely used to examine the effects of the loss of tumor suppressor 
genes known to have significant roles in human breast cancer, including P53 (115), BRCA1 
(209) and PTEN (111); and the effects of gain of function in oncogenes such as ERBB2 (69), 
MYC, HRAS (164) and CCDN1 (214). These models have confirmed the role of these genes in 
breast carcinogenesis. 
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Most mice models use the mouse mammary tumor virus (MMTV) or the whey acidic protein 
(WAP) as promoters to drive expression of an oncogene because their expression is restricted to 
the mammary gland, being highly active in luminal epithelial cells. In addition, some groups 
have used a keratin 14 (K14) promoter in order to direct the expression to basal cells and study 
lobular breast cancers (43).  However, transgene expression in these models usually extends 
throughout most of the ductal or lobular cells. Therefore, they are not good models of human 
breast cancer development; in which oncogene expression or loss of tumor suppressor function 
occur in a limited number of cells. 
Later, new transgenic models that combined the transgene expression control by these 
promoters (MMTV, WAP, K14 and others) with tetracycline (tet)- regulatable transgenes, Cre 
recombinase-mediated somatic gene deletion or activation (192) and inducible forms of Cre 
recombinase (by using fusion proteins with mutated oestrogen or progesterone receptors) (168) 
were also used to improve the spatial and temporal control of transgene expression. 
Although there are some histological differences in mammary gland tumors between human 
patients and animal models (31), many similarities between mouse and human have been 
identified: tumor formation resulted from multiple genetic mutations, tumors contained regions 
that resembled human breast cancer and genes associated with human cancer caused cancer in 
mice. Main drawbacks include that most tumors metastasize only to the lungs and that nearly all 
are hormone independent, while 70% of human breast cancers are hormone dependent. In 
addition, a comparative genomics approach to evaluate the molecular profiles of the most 
common transgenic mice used to study breast cancer comparing them with human tumor 
molecular expression profiles indicated that none of them was representative of the ER+ luminal 
A human subtype (74) . 
2.3.1. Trp53 mouse models of mammary gland carcinogenesis 
Homozygous Trp53 knockout mice develop spontaneous tumors that are mostly lymphomas and 
sarcomas before they reach 6 months of age and succumb to them by 10 months of age (45), 
while heterozygous mice that carry one wild type Trp53 allele rarely develop tumors before they 
are 9 months old. In addition, these p53+/- mice exhibit a wider array of tumors, but most of 
them consist of soft tissue sarcomas and lymphomas (191). Since early death due to lymphomas 
was supposed to be masking the development of breast tumors, several studies were done 
transplanting the mammary gland of p53-/- mice to a cleared fat pad of wild type p53+/+ mice 
(88). However the influence of the transplant process in the tumor development was not clear.  
To overcome this problem several experiments were done with conditional expression of mutant 
forms of Trp53 in epithelial cells of mammary glands. For example, when expressing 
conditionally a mutant R270H Trp53 allele in mammary glands  using the WAP promoter,  ER 
positive mammary gland tumors were obtained (205). A similar experiment using a mutant 
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Trp53 that was expressed under the MMTV or WAP promoters obtained spontaneous mammary 
gland tumors, in which a subset of them was ER positive and both lines MMTV and WAP 
transgenic mice produced metastasis to lung or liver (115).  
 
3. THE SLEEPING BEAUTY TRANSPOSON SYSTEM 
3.1. Insertional mutagenesis in cancer research 
 
Mouse models are widely used in cancer gene discovery due to several reasons: their small size, 
ability to breed in captivity, a relatively short lifespan and because they display extensive 
physiological and molecular similarities to humans. In addition, their genome has been entirely 
sequenced. Genetically engineered mouse models have allowed the study of gene function in 
vivo and the creation of models that recapitulate human cancer. Transgenic mice (created by 
pronuclear injection of a transgene or by embryonic stem cells manipulation) have been used for 
studying the effect of overexpressing an oncogene or inactivating a tumor suppressor gene. 
Transgenic constructs can be designed to restrict transgene expression to specific tissues and to 
control when and how long the transgene is expressed by adding specific regulatory elements. 
 These models have been useful to study the molecular function of a particular gene or a few 
genes, but they present some disadvantages when applied to the study of cancer biology. First, 
tumors develop through a multistep process, where mutations are gradually acquired, while in 
these models, the genes of interest are mutated simultaneously. Second, the mutation of interest 
is present in every cell of a tissue, while natural tumors develop from a single mutated cell. And 
finally, many mouse models show high penetrance and short latency, and hence the resulting 
tumors may not present many of the cooperating events that natural tumors acquire with time. 
To overcome these disadvantages, insertional mutagenesis has been proposed as an alternative 
tool for cancer gene discovery in the mouse. Forward genetic screens using somatic mutagens 
allows the identification of cancer candidate genes without the need of previous information 
about the gene or tumor type, facilitating the determination of new genes involved in 
carcinogenesis. Different mutagens have been used for this purpose: 
Chemical mutagenesis using agents such as N-ethyl-N-nitrosourea (ENU) is a highly efficient 
way of inducing tumors in mice, but the causal mutations can be hard to identify. 
Slow transforming retroviruses, like murine leukemia virus (MuLV) or mouse mammary 
tumour virus (MMTV) have been widely used for insertional mutagenesis in the mouse. 
Retroviruses induce tumors by inserting themselves into the mouse genome, which may lead to 
deregulation of a proto-oncogene or to inactivation of a tumor suppressor gene. Mutations that 
confer a growth advantage to the infected cell will be selected, and this may recapitulate the 
multistep progression of human tumors. These retroviruses contain viral genes flanked by two 
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long terminal repeats (LTRs) (Figure 10) Elements within the LTRs drive expression of the 
viral genes but can also disrupt the expression of host genes. 
 
Figure 10. Viral genes are flanked by LTRs, which consist of three parts: U3, R and U5 (187) . U3 
contains the enhancer and promoter sequences that drive viral transcription, the R domain 
includes the 5´capping sequences and the poly A signal. Gag, pro, pol and env encode the viral 
components required for assembly of viral particles. (Modified from Uren (187) ) 
 
Retroviruses can mutate host genes in a number of different ways. The most common 
mechanism is enhancer mutation, where the enhancer included in the LTRs upregulates 
expression of host genes. An alternative mechanism of mutagenesis is promoter mutation, 
where the retrovirus inserts in the sense orientation into the promoter region of a host gene, 
producing chimeric transcripts between the retrovirus and the murine gene. A third mechanism 
is the production of a truncating mutation by intragenic insertion, causing premature termination 
of gene transcription, resulting in either gene upregulation or inactivation (Figure 11)  
 
 
Figure 11. Retrovirus mechanisms of mutagenesis. The provirus is shown in blue and coding 
and non-coding exons are shown in red and white, respectively. A) Enhancer mutation. B) 
Promoter mutation C) Truncating mutation (Modified from Mattison (123)) 
 
According to this behavior, it is possible to identify either oncogenes or tumor suppressor genes 
by retroviral insertion mutagenesis. Retroviral insertion sites in the tumors mark the location of 
candidate mouse cancer genes, which are then identified through cloning and sequencing of the 
insertion sites. Hundreds of candidate genes have been identified in recent years using this 
approach (2). However, there are several limitations for the use of retrovirus in insertional 
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mutagenesis. The major limitation consists on its cellular tropism, limiting their mutagenesis to 
specific tissues such as mammary gland for MMTV and hematopoietic tissue for MuLV, so they 
are less efficient for cancer gene screening in other tumors. In addition, MuLV and other 
retroviruses do not efficiently infect non-dividing and slowly replicating cells and they do not 
infect tissues that have a basement membrane or mucin layer (197, 210). And finally, they show 
a strong preference for integrating near the promoter region of actively transcribed genes, which 
makes it difficult to efficiently mutagenize the entire genome. 
Transposon-based insertional mutagenesis provides an alternative to overcome the drawbacks 
of retroviruses for cancer gene discovery in the mouse. Transposons are DNA mobile elements 
that change their position within the genome. There are two types of transposons depending on 
their mechanisms of mobilization.  
Class I (retrotransposons) are mobilized using a RNA intermediate. They are transcribed and 
then reverse transcribed by enzymes encoded by the retrotransposon. The resulting DNA copies 
are mobilized into new sites in the genome.  
Class II refers to DNA transposons. They are mobilized using a “cut and paste transposition 
mechanism”, in which a transposase (encoded by the DNA transposon) catalyses the excision of 
the transposon from its original location in a given chromosome and then promotes its 
reintegration elsewhere in the genome. DNA transposons are also classified as autonomous, 
when they encode an active transposase enzyme and non-autonomous when they lack a 
functional transposase enzyme that needs to be supplied in trans for its transposition. 
Although transposon mutagenesis has been  successfully used in  genomic screens in organisms 
such as Drosophila melanogaster, Caenorhabditis elegans and plants (15), (35), it has not been 
used in vertebrates until recently. 
The Sleeping Beauty (SB) transposon is a synthetic transposon shown to have activity in mice 
(84). The SB transposon is a member of the family of Tc1/ mariner transposable elements that 
transposes by a “cut and paste” mechanism and was originally identified as a dormant 
transposable element in the genome of several species of salmonid fish. Directed mutagenesis 
was used to correct mutations that silenced the activity of the transposase enzyme (84), resulting 
in a transposon active in fish, but also in  mouse and human cells  (118), (85), (212), (52), (51). 
The SB transposon is flanked by two inverted repeats, left (IRL) and right (IRR), of ∼230 bp 
each, flanking a cargo sequence. The cargo sequence of the transposon can be any sequence of 
choice. However, transposition efficiency decreases with increasing cargo sizes, being 2 kbp the 
optimal transposon cargo size (64). Transposition occurs by binding of the transposase enzyme 
to specific binding sites within the IRL/IRR elements and subsequent excision of the transposon 
from the donor site and insertion elsewhere in the genome at a TA dinucleotide target site. The 
TA site is duplicated at the insertion site and the DNA breaks generated at the donor site are 
also repaired by the transposase (Figure 12). 
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Figure 12. The Sleeping Beauty (SB) transposon system. The SB transposon system consists of 
two parts: the transposase enzyme SB and the transposon. When both elements are found 
within the same host cell nucleus, the SB can bind to the inverted repeats of the transposon 
(IRR and IRL), excise the transposon from its original site and mediate insertion into a new TA 
dinucleotide site in the genome. The TA site is duplicated upon insertion, and flanks each end 
of the transposon at the insertion site and remains after the DNA breaks are repaired. The 
repair often leaves behind a footprint, for example (TACTGTA). Modified from Dupuy (49) 
 
3.2 The T2Onc2 transposon 
 
The first experiments performed using the SB system in mice involved the generation of 
transgenic mice that expressed the transposase enzyme specifically in the mouse germ line (52). 
These experiments resulted in such a low rate of transposition in the germ line that it was 
considered not to be a practical approach in cancer gene studies in the mouse, since cellular 
transformation into cancer cells requires several independent gene mutations. Transposon 
mutagenesis in somatic cells was the following approach used for cancer gene discovery. To 
this aim, the T2/Onc2 transposon was developed. T2/Onc2 is a modified SB transposon  that 
was designed to achieve higher rates of transformation in somatic cells of the mouse (50). Its 
cargo was designed to mimic retroviral insertion mutagenesis, being engineered with splice 
acceptors and polyadenylation sequences in both orientations to disrupt the expression of the 
genes in which they land.  It also contains sequences from the 5´LTR of the murine stem cell 
virus (MSCV LTR) to serve as promoter/enhancer elements to drive expression of nearby 
genes. The MSCV LTR is also followed by a splice donor site (SD). These characteristics make 
this transposon an adequate insertional mutagen for cancer gene identification because it can 
mutate both oncogenes and tumor suppressor genes. The splice acceptors (SA) and 
polyadenylation sequences (pA) on both strands allow the transposon to be able to truncate 
tumor suppressor gene transcripts when inserted in either the forward or reverse orientation. The 
promoter and the splice donor site (SD) serve to initiate transcription and splice into 
downstream exons to drive overexpression of oncogenes (Figure 13) 
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Figure 13. T2/Onc2 transposon structure. The T2/Onc2 transposon contains two inverted 
repeats (IR); the enhancer and promoter of MSCV 5’ LTR, and the splice donor (SD) and 
acceptor sites (SA). With this structure, it can cause overexpression, disruption in the 
expression or expression of truncated forms of the targeted genes. Modified from Dupuy (49)  
3.3. Sleeping Beauty models of cancer 
 
Insertional mutagenesis in mice for cancer gene discovery using the SB transposon involves the 
use of two mouse strains, one containing the transposase transgene  and another containing a 
multicopy concatemer of the transposon transgene. Transposon mobilization will therefore 
occur in the resulting offspring carrying both transgenes in their genome 
 
Figure 14. Transposon insertional mutagenesis in mice using the SB transposon. The progeny 
of transposase and transposon transgenic mice express the transposase causing mobilization 
of the transposon in the genome. Modified from Walrath JC (194) 
 
Several different approaches using SB insertional mutagenesis have been done in order to find 
candidate cancer genes in a variety of different cancer types. Currently, three different 
mutagenic transposons T2/Onc, T2/Onc2 and T2/Onc3 have been used in combination with two 
different transposase transgenes (SB10 and SB11) to model cancer in mice. Promoter sequences 
in the transposon cargo and transposase expression control have been modified depending on 
the cancer of study. The first experiments with transposon insertional mutagenesis in mice for 
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cancer gene discovery involved the use of the modified transposons T2/Onc and T2/Onc2 (33), 
(50). Both transposons share the same structure, being the only difference that T2/Onc contains 
a larger fragment of the Engrailed 2 splice acceptor (En2). Transgenic lines were established 
harboring multiple copies of T2/Onc or T2/Onc2 transposons within a concatemer carrying 
between 20-30 and 150-300 copies respectively. These mice were mated to transgenic mice 
expressing the transposase gene in order to obtain mice that underwent transposition events. 
T2/Onc mice were bred to transgenic mice carrying  the SB10 transposase transgene expressed 
under the control of the ubiquitous CAGGS promoter (33), while T2/Onc2 transgenic mice were 
crossed to transgenic mice carrying the more active SB11 transposase version (50) inserted into 
the Rosa26 locus (Rosa26-SB11), also ubiquitously expressed. Double transgenic mice 
containing the T2/Onc transposon did not present spontaneous tumor formation. However, 
T2/Onc was able to accelerate sarcomas tumor formation in mice deficient for the p19 Arf tumor 
suppressor. Double transgenic mice offspring containing the T2/Onc2 transposon and the SB11 
transposase suffered from embryonic lethality. All the animals that survived developed 
aggressive lymphomas within 10 weeks of age (50). When Rosa26 SB11 mice were bred to 
T2/Onc mice, the offspring died at a mean age of 6 months, due primarily to 
lymphoma/leukaemia. Some of them also harbored infiltrating gliomas (32) and 
hyperproliferative prostate lesions (142). In these experiments using T2/Onc and T2/Onc2 
transposons, clonal transposon insertions were found associated to tumor development and 
progression. In addition, at difference  to what happens in retroviral insertional mutagenesis, 
transposon insertions were widely distributed across the genome, being the only exception to 
this assumption the “local hopping” phenomenon, which is defined as the tendency of the SB 
transposon to transpose to sites close to the concatemer.  Subsequent experiments involved a 
conditional SB11 transposase that allowed the study of insertional mutagenesis in a broad range 
of tumors. A conditional Rosa 26-SB11 transposase allele was generated in which loxP sites 
flanked an upstream EGFP cassette (Figure 15). In this way, SB11 was only expressed when 
Cre recombinase deleted the floxed EGFP cassette (Figure 15). Using this approach, candidate 
cancer genes were identified in B-cell malignancies (53), colorectal cancer (170), hepatocellular 
carcinoma (95) and pancreatic adenocarcinoma (121) 
 
Figure 15. Rosa-SB11 allele designed for condicional transposase expression. (Modified from 
Dupuy (53) ) 
 
The recently developed T2/Onc3 transgene is identical to T2/Onc2 except that the MSCV 
5’LTR was replaced by the CMV enhancer/ chicken b-actin promoter (CAG). This promoter is 
strongly expressed in a variety of cell types including epithelial cells. Experiments using 
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transgenic mice harboring 10-20 copies of this transposon that were bred to Rosa26-SB11 mice 
obtained a double transgenic offspring that developed a variety of malignancies, being the most 
common hepatocellular carcinoma liver, lung adenomas and SCC (53) 
 
4. IDENTIFICATION OF CANDIDATE CANCER GENES 
4.1. Identification of SB-tagged genes 
 
SB transposon insertion sites within the mouse genome can be identified because the transposon 
sequence is different from the murine genome. Therefore, mouse sequences adjacent to the 
insertion sites can be amplified by ligation-mediated PCR methods (LM- PCR) using primers 
targeting the IRR and the IRL within the transposons (104). The PCR products are then 
sequenced and used to map the transposon insertion sites to the mouse reference genome, so the 
gene or genes likely to be affected by each transposon insertion can be identified, as well as the 
orientation of the transposon with respect to the gene. The first experiments performed with SB 
transposons as mutagenic agents followed a shotgun cloning approach where a plasmid library 
of the LM-PCR products from each individual tumor was created. After that, individual clones 
from each library were sequenced by Sanger methods to identify the transposon-genomic DNA 
junctions found within each tumor (50), (33), (32).  
However, this technique presented notable limitations, such as laborious library production and 
a limited number of independent clones that could be sequenced..In order to overcome the 
shotgun cloning limitations, the technique was replaced with a novel method that generates LM-
PCR products that can be directly sequenced on the Genome Sequence FLX platform 
(454/Roche) (53), (95), (170), (16). This approach represented a 3-fold increase in the sequence 
coverage over the traditional Sanger sequencing. In addition, recent work has shown that many 
hundreds of independent insertion events can be identified in each tumor sample (170); so, it is 
necessary to obtain enough sequence depth in order to identify all the insertion events present in 
the tumor samples. The pyrosequencing 454/Roche platform was chosen for transposon 
insertion sites identification because its longer read length (>100bp) allowed barcoding the 
samples, so multiple samples could be processed in a single sequence run, making at the same 
time possible both the verification of the transposon structure and the adequate mapping of the 
transposon/mouse genomic junction sequence.  
However, it has been recently seen that pyrosequencing data obtained from repeated analysis of 
the same samples only identify part of the original insertion sites present in each tumor sample 
(171). Improvements in the annotation of short sequences and the sequence read length for the 
Illumina sequencing platform (~75bp)  made transposon insertion site sequencing possible using 
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this technology, that in adidtion to being more economical, results in a greater sequence depth 
than 454/Roche pyrosequencing.  
4.2. Determination of common insertion sites 
 
Common insertion sites (CIS) are genomic regions that have been hit by transposon insertions 
in multiple tumors. Since insertions occur independently in each tumor, it is unlikely to find 
insertions in the same locus from multiple tumors by chance alone.  These insertions hotspots 
are likely the result of selective advantage as a consequence of the presence of these mutated 
loci in tumor cells, so CIS regions probably represent candidate cancer genes. Two statistical 
methods have been developed for CIS identification: the Gaussian Kernel Convolution and the 
Monte Carlo simulation. Both methods calculate the expected number of transposon 
integrations, taking into account the exact distribution of TA dinucleotides across the genome 
and determine if insertion sites found in the tumors have been targeted more than expected by 
chance. One thing that is necessary to do before CIS analysis is the removal of local hopping 
transposition events (i.e., discard integrations in the same chromosome in which the concatemer 
is originally located), to prevent false CIS identification. 
Analysis of CIS in Sleeping Beauty transposon-induced tumors has identified both known and 
novel cancer causing genes, both oncogenes and tumor suppressor genes. Frequently, the 
information obtained in transposon mutated mouse models has been validated by the study of 
human tumoral samples, thus confirming the driver nature of the characterized gene alterations 
in human cancer development.  
Examples of important cancer genes characterized in transposon-mediated approaches  are 
Notch1 in SB-induced T-cell lymphoma (50), Apc in colorectal cancer (170), Braf in sarcomas 
(33), Pde4D in prostate cancer (142), EGFR in hepatocellular carcinoma (95) and Csf1 in 
astrocytomas (16).  
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OBJECTIVES 
 
Many forms of Cancer arise as a result of somatic mutations in genes regulating growth 
and differentiation of cells. In most tumors, multiple genes are usually affected. The 
number and nature of genes needed to drive cancer development can vary between 
different tumor types and recent cancer genome studies have determined that the 
number of genes with transforming potential is greater than expected. In addition, there 
are many passenger mutations in the tumors that are not casually implicated in 
oncogenesis. Therefore, it is still necessary to define more precisely which combination 
of mutations is required to drive tumor growth. Transposon-mediated mutagenesis 
allows the development of cancer and the identification of driver mutations that 
contribute to carcinogenesis. 
 
The main purpose of this study was to use the Sleeping Beauty transposon system to 
identify novel candidate cancer genes that contribute to human skin cancer. The 
research objectives were: 
 
• Generation of transgenic mice containing mutagenic transposons active in skin, 
other  stratified epithelia and exocrine glands, both in wild type and cancer-
prone genetic backgrounds, and verification of the correct activation of the 
system in the transgenic mice. 
• Generation of tumors in these mice, and analysis of the histopathological 
features of the resulting tumors. 
• Identification of the transposon-tagged candidate cancer genes within the mouse 
tumors through the use of next-generation sequencing. 
• Validation of the candidate mouse cancer genes in human tumor samples  
  42 
  43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
  44 
 
Materials and Methods 
 45 
1. GENERATION OF TRANSGENIC MICE LINES 
 
K5-SB11 (named as SB) transgenic mice had been generated previously in our laboratory by 
microinjection of a K5-SB11 construct, including the SB11 transposase (a generous gift of Dr. 
Perry Hackett, University of Minnesota) under the control of the regulatory sequences of the 
bovine keratin K5 gene (143) into (C57BL/6J X DBA/2J) F2 (B6D2) embryos using standard 
techniques (75). Transgenic lines were established by crossing the transgenic mice with 
B6D2F1 mice. Heterozygous T2Onc2 mice (named as T2: lines 6070 and 6113), containing 
several hundred copies of T2Onc2 transposon in chromosomes 4 and 1 respectively) were 
provided by Dr. Adam J. Dupuy, University of Iowa(50).  
Double K5-SB11/T2Onc2 (named as SB/T2) transgenic mice, containing both the SB11 and 
T2Onc2 transgenes were generated by interbreeding of heterozygous SB and T2 mice.  
Triple K5-SB11/T2Onc2/Tg.AC (SB/T2/Tg.AC) transgenic mice were generated by mating 
heterozygous SB/T2 mice to Tg.AC heterozygous mice that were acquired from Taconic Farm 
Inc (Germantown, NY, USA). The resultant SB/T2/Tg.AC mice contained the three transgenes 
(SB11, T2Onc2 and Tg.AC) in a 75% B6D2 / 25% FVB genetic background. 
Heterozygous p53+/- transgenic mice were obtained by mating conditional mutants Trp53F2-10 
mice, (that carried  floxed Trp53 alleles in a FVB genetic background provided by the 
laboratory of Dr. Anton Berns (Netherlands Cancer Institute),(91)) to K5-Cre transgenic female 
mice (that cause ubiquitous cre-mediated recombination of floxed alleles in preimplantation 
embryos) (144). Triple transgenic K5-SB11/T2Onc2/p53+/- mice (SB/T2/p53+/-) were 
generated by mating heterozygous SB/T2 to heterozygous p53+/- mice. 
In these crosses, different genetic combinations lacking the transgenes T2Onc2 (SB/Tg.AC and 
SB/p53+/-), the transposase SB11 (T2/Tg.AC and T2/p53+/-) or both SB and T2Onc2 trasgenes 
(p53 +/-) were also generated as control mice for the experiments. 
 
Mice were maintained on standard rodent diet and kept under a 12h light-12h dark cycle. All 
experimental procedures were performed according to European and Spanish laws and 
regulations (European Convention ETS 123 on the use and protection of the vertebrate 
mammals used in experimentation and other scientific purposes; Spanish R.D 1201/2005 of the 
Ministry of Agricultural, Food and Fisheries on the protection and use of animals in scientific 
research) and approved by our institution Ethics Committee. Mice were euthanized in a CO2 
chamber for tumor extraction or when they presented notable deterioration, following FELASA 
and CIEMAT regulations. 
 
 
Materials and Methods 
 46 
2. ISOLATION OF GENOMIC DNA 
2.1. Tail tips biopsies of mice 
Tail tip biopsies were digested in 700µL of lysis buffer (100mM Tris-HCl pH 8.5, 5mM EDTA, 
0.2% SDS, 200mM NaCl and 100µg proteinase K/ml) overnight at 55ºC. DNA was precipitated 
with 1 volume of isopropanol, washed with 70% ethanol and  resuspended in TE buffer (10mM 
Tris-Cl, 1mM EDTA, pH: 8.0) 
2.2. Epidermal and dermal DNAs 
In order to isolate the epidermal and dermal DNAs from newborn or adult animals, back skin or 
tail skin, respectively were incubated for 2 min at 60ºC and epidermises were then mechanically 
separated from dermal tissue under a dissecting microscope. After that, dermal and epidermal 
DNAs were extracted as described for tail biopsies.  
2.3. Tumors 
Tumor samples were removed from the euthanized animals, minced and digested in 700 µL of 
lysis buffer (50 mM Tris-HCl pH 8,5, 100 mM EDTA, 1% SDS, 100 mM NaCl and 100 µg/ml 
proteinase K) overnight at 55ºC. DNA was then precipitated with 250 µL of saturated NaCl and 
500 µL of isopropanol, and washed with 70% ethanol. The DNA was resuspended in TE buffer 
(10 mM Tris-Cl, 1 mM EDTA, pH 8.0). 
For some tumor samples, the QIAGEN Genomic DNA 20/G kit isolation was used, according to 
the manufacturer protocol. 
 
3. GENOTYPING OF TRANSGENIC MICE 
 
Mice were genotyped by PCR analysis of tail DNA. The primers used for DNA amplification 
are listed below (Figure 17). For amplification of the SB11 and T2Onc2 transgenes, the PCR 
program used consisted of an initial denaturing step of 94ºC for 3 min; 40 cycles of denaturing 
at 94ºC for 15s, annealing at 55ºC for 30s and extension at 72ºC for 45s; followed by a final 
extension at 72ºC for 3 min.  
For PCR amplification of the Tg.AC transgene and the p53 gene,, conditions consisted of an 
initial denaturing step of 94ºC for 5 min; 29 cycles of denaturing at 94ºC for 30s, annealing at 
58ºC for 30s and extension at 72ºC for 50s; followed by a final extension at 72ºC for 5min. 
PCR products were then separated on a 1.7 % agarose electrophoresis gel in TBE 1X (Tris-
borate-EDTA: 89mM Tris-borate, 2mM EDTA, pH 8) and 1µg/mL ethidium bromide (Sigma). 
A DNA ladder was added to estimate the size of the amplified PCR products (DNA Molecular 
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Weight Marker IX, Roche and Lambda DNA marker, Bioron). The DNA was visualized using a 
UV transilluminator and Quantity One software (Biorad) 
3.1. Genotyping PCR reaction 
Forward and reverse primers to detect SB11 and T2Onc2 transgenes were combined in an equal 
mix to facilitate detection of both transgenes in only one PCR reaction. This was possible 
because the PCR amplified fragments for both genes are of different size. PCR reagents and Taq 
polymerase were purchased from Invitrogen. 
Reaction SB11/T2Onc2 p53
DNA 1 µL 1 µL
Water 12.8 µL 11.8 µL
Buffer 10x 2 µL 2 µL
Mg 50mM 1 µL 1 µL
Reverse primer 0.5 µL 1 µL
Forward primer 0.5 µL 1 µL
dNTPs 2mM 2 µL 2 µL
Taq polymerase 0.2 µL 0.2 µL  
Figure 16. PCR reaction setup for genotyping 
 
GENES PRIMERS SEQUENCE (5'-3')
b-globin 1 TTCAGGGTGTTGTTTAGAATGG
b-globin 2 CAATAAGAATATTTCCACGCCA
T2Onc2 Left CAGTTGAAGTCGGAAGTTTA
T2Onc2 Right GGAATTGTGATACAGTGAAT
Forward TGGCATTTCTTCTGAGCAA
Reverse TTGGACAAACTACCTACAGAGAT
10R GAAGACAGAAAAGGGGAGGG
1F CACAAAAACAGGTTAAACCCAG
SB11
T2ONC2
Tg.AC
p53 null
 
Figure 17. Primers used for genotyping 
 
4. EXCISION PCR 
 
Excision PCR was used to study transposon mobilization in SB/T2 double transgenic animals. 
The primers used were Excision1 (5´- TGTGCTGCAAGGCGATTA -3’) and Excision2 (5´- 
ACCATGATTACGCCAAGC -3´). Conditions for PCR were: initial denaturing step of 95ºC 
for 5 min; 40 cycles of denaturing at 95ºC for 30s; annealing at 50ºC for 30s and extension at 
72ºC for 1min20s; followed by a final extension at 72ºC for 3 min. PCR products were 
separated on a 1% agarose electrophoresis gel following the same procedure described in 3. 
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5. RNA ISOLATION 
5.1 Mouse tissue 
Mouse normal skin or tumor samples isolated from transgenic mice were disrupted and 
homogenized in  1.5 mL Trizol reagent (Invitrogen) using a Polytron homogenizer. Then, for 
phase separation, 0.3 mL of CH3Cl was added to samples. After that, samples were vortexed 
vigorously for 15s and incubated at 5-10 min room temperature. Next, samples were centrifuged 
(14000 rpm for 10 min at 4ºC) and the aqueous phase was preserved for total RNA isolation. 
RNA was precipitated with isopropanol and washed with 70% ethanol. RNA was resuspended 
in 100µL of RNase- free water.  
5.2. Human tissue 
Fresh tissue samples were obtained from ambulatory patients in the surgical service of the 
Hospital Gregorio Marañón. All samples were obtained with an informed consent, according to 
the ethical guidelines. A 4mm punch biopsy was obtained from the center of the tumor tissue, 
and another biopsy was taken from healthy skin outside the tumor margin. The margins of the 
tumors were sent to the pathology service to confirm that there was not malignant tissue. 
Biopsies were immersed in RNAlater (Ambion) for preservation immediately after extraction. 
After 24h, RNA later was removed and samples were frozen at -70ºC until processed. Frozen 
samples were then disrupted and homogenized using Trizol reagent (Invitrogen) using a 
Polytron homogenizer, as described above (5.1). Total RNA was then purified using RNAeasy 
columns (QIAGEN) and RNA quality was checked using phosphate agarose gels, 
spectophotometry analysis and an Agilent Bioanalyzer 2100. 
 
6. NORTHERN BLOT 
20 µg of RNA isolated from mice epidermis were run on agarose gels using MOPS buffer 
(SIGMA) and 6% formaldehyde. Then, the gel was transferred overnight to nylon membranes 
(Amersham, GE Healthcare) using 10x SSC (saline-sodium citrate) buffer. After that, the 
membrane was UV-irradiated and kept for 2 hours at 70 ºC. The membrane was then hybridized 
with a SB11 DNA probe and a 7S RNA probe to normalize loading differences. 
 
7. SOUTHERN BLOT 
For the analysis of transposition in tissues and tumors from SB/T2 mice, genomic DNA was 
digested with BamH1 and blotted using standard techniques(167). The membrane was 
hybridized with a 278bp PCR-amplified-probe from the region of T2/Onc2, between the IRL 
and the MSCV promoter. Hybridation with Thy1 was performed to normalize loading 
differences 
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8. REVERSE TRANSCRIPTION 
 
The cDNAs were prepared from 2 µg of total RNA isolated from human tumors using the High 
Capacity RT kit (Applied Biosystems) according to the manufarturer’s instructions. 
 
9. REAL TIME-PCR 
 
Quantitative real-time PCR was performed using an ABI 7500 Fast Instrument (Applied 
Biosystems) and predesigned probes from Taqman Gene Expression assays (Applied 
Biosciences) or from the Universal Probe Library (Roche). Probe selection and primer design 
was done using the Probe Finder Assay software (Roche) for every gene in the expression 
analysis study. Normalization was performed using the geometrical means of four genes (TBP, 
βACT, HPRT and GUSB) according to the recommended procedure (189). All samples were 
assayed at least twice and statistical analysis was performed using SPSS and MeV (153). 
 
 
Figure 18. Primers and probes from Universal Probes Library and ABI used for Real Time 
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10. WESTERN BLOT 
 
Protein extracts from mouse  tissues were obtained by homogenization in a liquid N2-frozen 
mortar followed by 3 freezing/unfreezing cycles  in lysis buffer (Hepes 200 mM pH7.9, glycerol 
25%, NaCl 0.4M, EDTA 1mM, EGTA 1mM and Nonidet P40 1%)   supplemented with 
proteases inhibitors: DTT (2.5mM) aprotinin/leupeptin (10 mg/µL), PMSF (1mM), 
orthovanadate (1mM) and fosfatases inhibitors: NaPPi (1mM) and FNa (5 mM) . Protein 
concentration was determined using the colorimetric Bradford method (BioRad). Denatured and 
reduced sample proteins were separated by 4-12% gradient polyacrilamyde gel electrophoresis 
(SDS-PAGE) using a NuPAGE MOPS running buffer (Invitrogen). 40µg of the total protein 
extract from each sample and a protein ladder (BioRad) were used for gel electrophoresis. 
Samples were then transferred to a nitrocellulose membrane (Invitrogen) using transfer buffer 
(33 mM Tris, 19,4mM Glycine) with 10% of methanol. Membranes were incubated with 
blocking buffer (5% milk and 0.1% Tween 20 in TBS (Tris-Cl 20 mM, 137 mM NaCl, pH 7.6) 
for 1h at room temperature. A monoclonal anti-SB antibody (R&D Systems) was used at 1:500 
dilution and incubated o/n at 4ºC with shaking. Peroxidase-conjugated AffiniPure Donkey Anti-
Mouse (Jackson) was used as a secondary antibody at 1:2000 dilution. β-Actin antibody (Santa 
Cruz) was used as a loading control at 1:2000 dilution. These antibodies were incubated 1h at 
room temperature with shaking. All primary and secondary antibodies were diluted in a solution 
of 0.1% Tween 20 and 1% of BSA in TBS (Tris-Cl 20 mM, 137 mM NaCl, pH 7.6). 
Nitrocellulose membranes were washed 3 times with TBS-Tween 1% between antibody assays. 
The Super Signal Wet Pico Chemiluminescent Substrate (ThermoScientific) was used for 
secondary antibody detection, following the manufacturer’s instructions and the membranes 
were exposed on a photographic film (Amersham Hyperfilm ECL). 
 
11. IMMUNOHISTOCHEMISTRY ANALYSIS 
 
Isolated tissues from mouse origin were fixed in 4% formaldehyde in PBS or 70% ethanol and 
then paraffin-embedded.  Deparaffinized sections were stained with hematoxylin and eosin. For 
samples fixed in formaldehyde, a 10mM citrate buffer or a EDTA buffer: 10 mM Tris Base, 1 
mM EDTA Solution, 0.05% Tween 20, pH 9.0 (for NSD1) was used for antigen retrieval. 
Samples were the incubated in a 0.3% H2O2 solution to block the endogenous peroxidase 
activity. In addition, in order to avoid non-specific reactions, selected sections were incubated 
with a solution of 2.5% fetal bovine serum in PBS during 30 min at room temperature. Selected 
sections were then immunostained with primary antibodies (Figure 19) in PBS and BSA 1% at 
4ºC o/n. After that, sections were incubated with the adequate secondary antibodies (Figure 20) 
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in PBS and BSA 1% for 1h at room temperature. The immunoreaction was detected using the 
ABC avidin-biotin-peroxydase conjugate system (ABC kit, Vectastain). DAB was used as a 
chromogen (Peroxidase Substrate Kit DAB, Vector Laboratories). Samples were then 
counterstained with hematoxylin and visualized under an optical light microscope.  
 
12. IMMUNOFLUORESCENCE ANALYSIS 
 
Deparaffinized sections that were fixed in ethanol were used for immunofluorescence analysis, 
so antigen retrieval was not necessary. Double staining was done incubating primary antibodies 
against CD34 and SB in the same tissue section. Skin sections were incubated with primary 
antibodies against CD34 and SB diluted in 4% BSA in PBS at 4ºC o/n. Biotinilated anti-rat and 
texas red conjugated anti-mouse secondary antibodies were diluted in 4% BSA in PBS and 
added to the sections, then incubated for one hour at room temperature. After three washes, anti-
streptavidin FITC-conjugated secondary antibody was added to the sections and incubated for 
1h at room temperature. After that, sections were mounted using a solution of Mowiol 
containing DAPI. Slides were seen under a Zeiss Axioplan2 imaging fluorescence microscope. 
Images were taken using a digital camera AxioCam MRm (Zeiss) and processed using 
AxioVision Rel 4.6 software and Corel Photo Paint11. 
 
PRIMARY ANTIBODIES 
ANTIBODY SOURCE SUPPLIER DILUTION REFERENCE
K5 Rabbit polyclonal Covance 1:1000 IHC PRB-160P
SB11 Mouse monoclonal R&D Systems 1:50 IHC/IF 
1:500 WB
MAB2798
Nsd1 Rabbit polyclonal Bethyl 1:50 IHC IHC-0027
Pard3 Rabbit polyclonal Abcam 1:50 IHC ab64646
Ras GAP 120 
(Rasa1)
Mouse monoclonal Santa Cruz 
Biotechnologies
1:50 IHC SC-63
Neurofibromin 
(Nf1)
Rabbit polyclonal Santa Cruz 
Biotechnologies
1:50 IHC SC-67
CD34 Rat monoclonal eBiosciences 1:50 IF 14-0341
 
Figure 19. List of primary antibodies used in Western Blot and immunohistochemistry assays 
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SECONDARY ANTIBODIES 
TARGET SPECIES CONJUGATE SUPPLIER DILUTION
Mouse Biotin Jackson 1:1000
Mouse Texas Red Jackson 1:200
Rabbit Biotin Jackson 1:1000
Rat Biotin Jackson 1:500
Streptavidin FITC BDPharmigen 1:250
 
Figure 20. List of secondary antibodies used in Western Blot and immunohistochemistry assays 
13. DMBA/TPA CARCINOGENESIS ASSAY 
 
The dorsal skin of SB/T2 and SB/T2/Tg.AC mice was shaved (approximately an area of 8 cm2) 
2 days prior the treatment. SB/T2/Tg.AC mice were treated with 12-O-tetradecanoylphorbol-13-
acetate (TPA, Sigma, 5 µg in 200 µL acetone) twice a week for 20 weeks. SB/T2 mice were 
treated one week before promotion with TPA with a single dose of 200 nmol of 7,12-
dimethylbenz(a)anthracene (DMBA, Sigma) (100 µg in 200 µL acetone). Mice were examined 
weekly for the presence of tumors. 
14. MICE TUMOR COLLECTION 
 
Isolated mice tumors were collected in: 
• Formaldehyde (4%) in PBS or in ethanol (70%) and subsequent paraffin embedding for 
immunohistochemistry analysis.  
• Liquid nitrogen and storage at -80 C for RNA/protein assays 
 
15. AMPLIFICATION AND SHOTGUN CLONING OF TRANSPOSON 
INSERTION SITES 
15.1. SplinkTA-PCR 
First, 3µg of genomic DNA isolated from tumors was digested with HindIII, XhoI and PvuII 
(New England Biolabs, NEB) restriction endonucleases for 2h at 37ºC. 
HindIII 3 µL 
XhoI 3 µL
PvuII 3 µL 
Buffer NEB 10 µL
BSA 1 µL
Water Up to 100 µL
DNA 3 µg
Reaction setup
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The digestion products were purified using the QIAquick PCR purification kit (QIAGEN) 
according to the manufacturer’s instructions. To achieve efficient ligation of genomic DNA 
fragments to splinkerettes, DNA fragments were modified using Taq polymerase to form sticky 
ends through the terminal non-templated adenosine addition reaction. For these adenosine 
addition reactions, each purified, digested DNA sample (50 µL) was incubated with the 
following PCR mix during 5 min for 72ºC. PCR reagents and Taq polymerase were purchased 
from Invitrogen. 
Buffer 10x 6 µL
Mg 50mM 1,8 µL
dATPs 10mM 1,2 µL
Taq polymerase 1 µL
Digested DNA 50 µL
Reaction setup
 
 
After this reaction, another round of DNA purification was done using the QIAquick PCR 
purification kit (QIAGEN). 
The SplinkTA tail was generated by mixing equal molar amounts of the olignonuleotides 
splinkerette (the hairpin oligonucleotide) and PrimerLongTA (including an extra T) and 
incubating them for 3 min at 94 -100 ºC and then slowly cool down to room temperature (25ºC). 
After that, the SplinkTA was ligated to the extension products using T4 DNA ligase (New 
England Biolabs) by overnight incubation at 16ºC, followed by DNA purification with the 
QIAquick PCR purification kit. 
Buffer 2 µL
T4 DNA ligase 2 µL
DNA 5 µL
Splinker 5 µL
Water 6 µL
Reaction setup
 
 
Then, the resulting products were digested using BamH1, followed by another round of DNA 
purification using the QIAquick purification DNA kit (QIAGEN). This digestion prevents the 
amplification of transposons within the concatemer. All the reagents were from New England 
Biolabs. 
Buffer NEB 5 µL
BSA 0,5 µL
BamH1 1 µL
Water Up to 50 µL
DNA 3 µγ
Reaction setup
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After that, two primary PCR reactions were performed using 1µL of resulting DNA from the 
previous reaction in order to amplify transposon-genomic junctions from the right and left sides 
of the transposon. One was done using primers that annealed to the splinkerette (primerette1, 
complementary to PrimerLongTA) and the left inverted repeat side (IRDRL1) of the transposon 
and the other one included primers that annealed to the splinkerette (primerette1) and the right 
inverted repeat side of the transposon (IRDRR1).  Taq polymerase and the rest of reagents were 
from Invitrogen. 
 PCR conditions were: denaturation at 95º C for 3min, followed by 10 cycles of 95º C for 15s; 
70º C for 2 min; 20 more cycles of 95º C for 15s; 65 ºC for 2 min; and a final extension at 72 ºC 
for 7 min. 
DNA 2 µL
Buffer 10x 5 µL
dNTPs 10mM 2 µL
Primerette1 0,5 µL
IRDRR1 or IRDRL1 10 µM 0,5 µL
Taq Platinum polymerase 1 µL
Mg 50mM 1,5 µL
Water 38,5 µL
Reaction setup
 
 
Then, for each case a nested PCR was done using 2µL of DNA from the previous reactions and 
primers that annealed to the splinkerette (primerette 2, complementary to PrimerLongTA) and 
either to the transposon left side (IRDRL2) or right side (IRDRR2).  
DNA 2 µL
Buffer 10x 5 µL
dNTPs 10mM 2 µL
Primerette2 0,5 µL
IRDRR2 or IRDRL2 10µM 0,5 µL
Taq Platinum polymerase 1 µL
Mg 50mM 1,5 µL
Water 38,5 µL
Reaction setup
 
 
PRIMERS SEQUENCE (5´-3)
Splinkerette CATGGTTGTTAGGACTGGAGGGGAATCAATCCCCT
PrimerLongTA CCTCCACTACGACTCACTGAGGGCAAGCAGTCCTAACAACCATGT
IRDRR1 GCTTGTGGAAGGCTACTCGAAATGTTTGACCC
IRDRL1 CTGGAATTTTCCAAGCTGTTTAAAGGCACAGTCAA
Primerette1 CCTCCACTACGACTCACTGAAGGGC
Primerette2 GGGCAAGCAGTCCTAACAACCATG
IRDRR2 CCTCCACTACGACTCACTGAAGGGC
IRDRL2 GACTTGTGTCATGCACAAAGTAGATGTCC  
Figure 21.  List of primers used for SplinkTA generation and PCR reactions. 
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15.2. Cloning and sequencing 
PCR products were run in a 1.3% agarose gel and individual chosen bands were purified using 
the Illustra GFX PCR DNA and Gel Band purification kit (GE Healthcare) according to the 
manufacturer’s instructions. 
 After that, the purified PCR products were cloned into a TOPO TA vector (pCR2.1) using the 
TOPO TA Cloning kit (Invitrogen), followed by transformation of XL-Blue competent cells. 
Colonies were grown on agar plates and positive colonies containing the DNA fragments were 
picked and cultured in liquid medium. Isolated DNA from cultures was then sequenced using 
universal primers (M13) on a 3730 DNA Analyzer (Applied Biosystems).  
15.3 Sequence analysis 
The resulting sequences were analyzed using the Insertional Mutagenesis Mapping and Analysis 
Tool (iMapper) (http://www.sanger.ac.uk/cgi-bin/teams/team113/imapper.cgi.).  
Using this tool sequences were scanned and trimmed to remove the splinkerette (linker) 
sequence and sequences derived from the transposon insertions. Contaminating sequences 
derived from chimeric genomic fragments, vector or transposon concatemer were also removed. 
After that, resulting sequences were mapped against the mouse Ensemble genome (NCBI 
mm37) using a SSAHA algorithm, and these regions were then annotated. Genes were defined 
including 10kb of both 5’ and 3’ flanking regions. (Figure 22) 
 
 
Figure 22. The iMapper tool identifies a transposon tag sequence and the restriction enzyme 
site within a DNA sequence read and the clipped sequenced is then mapped onto the 
Ensemble genome. (Modified from DJ Adams (101)) 
 
 
16. HIGH TROUGHPUT SEQUENCING 
16.1. Pyrosequencing using 454/Roche 
First, 2µg of isolated DNA from each tumour sample was digested with BfaI or NlaIII 
restriction enzymes to split the left (IRL) and right (IRR) inverted repeats of the transposon. The 
digestion was incubated o/n at 37ºC. 
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NlaIII or BfaI 1 µL 
Buffer NEB 10x 4 µL
BSA 10x 4 µL
Water Up to 40 µL
DNA 2 µg
Reaction setup
 
These genomic-transposon junction fragments were amplified by ligation-mediated PCR (LM- 
PCR) using adaptors that attach to the transposon-genomic DNA junctions after digestion and 
facilitate the PCR amplification of these fragments. 
A couple of adaptors were generated to join to each side of the transposon, one to the right side 
(IRR) and the other to the left side (IRL). The adaptors were generated by mixing equal molar 
amounts of linker+ and linker- primers and heating them to 95ºC for 5min. Then, the mixture 
was allowed to slowly cool down to room temperature (25ºC).  After that, the adaptors were 
ligated to the genomic fragments using T4 DNA ligase. The reaction was performed o/n at 16 
ºC.  
Buffer NEB 10x 2 µL
T4 DNA ligase 1 µL
DNA 10 µL
Adaptor 1,5 µL
ATP 10mM 2 µL
Water 3,5 µL
Reaction setup
 
Then, the resulting DNA was digested using BamHI o/n at 37ºC, in order to prevent transposons 
within the concatemer from being amplified. 
After that, two primary PCR reactions were performed using 2µL of resulting DNA from the 
ligation reaction in order to amplify transposon genomic junctions from the right and left sides 
of the transposon. One was done using primers that annealed to the adaptor (linker primer long) 
and the left inverted repeat side (IRL1) of the transposon and the other one included primers that 
annealed to the adaptor (linker primer long) and the right inverted repeat side of the transposon 
(IRR1). The Taq polymerase and reagents were purchased from New England Biolabs. 
DNA 2 µL
Buffer 10x 5 µL
dNTPs 10mM 1 µL
Linker primer long 10µM 0,5 µL
IRR1 or IRL1 10µM 0,5 µL
Taq Platinum polymerase 0,5 µL
Mg 50mM 2 µL
Water 38,5 µL
Reaction setup
 
After that, two nested PCRs were done using 2µL of a 1:50 dilution of the former PCR 
products, primers that annealed to the adaptor (linker pyro), and primers that contained unique 
sequences (A/B) which were added to the 5’ ends of the linker pyro primer (A) and the 
transposon specific primer (B). These A/B tags were used for amplicon sequencing on the high 
throughput sequencer Roche/454. In addition, the transposon specific primers also contained a 
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10bp barcode sequence added to the 5’ end of these primers and were used for tumor ID sample 
tracking (Figure 23) 
Diluted primary PCR DNA product (1:50) 2 µL
Buffer 10x 10 µL
dNTPs 10mM 2 µL
IRR or IRL Barcoded primers (includes A tag) (10µM) 1 µL
Linker pyro (includes B tag) (10µM) 1 µL
Taq Platinum polymerase 1 µL
Mg 50mM 4 µL
Water 79 µL
Reaction setup
 
 
 
 
Figure 23.  Scheme representing the LM PCR protocol to amplify transposon-genomic junctions 
from genomic DNA isolated from SB/T2 tumors. DNA is digested using BfaI or NlaIII enzymes. 
Double stranded adaptors are then ligated to the ends of genomic fragments. Then, a primary 
and secondary PCR are performed using specific barcoded primers that include the necessary 
sequences for direct sequencing on 454/Roche platform 
 
PRIMERS SEQUENCE (5´-3)
IRR linker + GTAATACGACTCACTATAGGGCTCCGCTTAAGGGACCATG
IRR linker - Phos-GTCCCTTAAGCGGAC-C3-spacer
IRL linker + GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC
IRL linker - Phos-TAGTCCCTTAAGCGGAG-C3spacer
IRR1 GCTTGTGGAAGGCTACTCGAAATGTTTGACCC
IRL1 CTGGAATTTTCCAAGCTGTTTAAAGGCACAGTCAAC
Linker primer long GTAATACGACTCACTATAGGGC
Linker pyro GCTTGCCAGCCCGCTCAGAGGGCTCCGCTTAAGGGAC  
Figure 24. List of primers used in the adaptor and PCR reactions. Barcoded primers are listed in 
supplementary materials 
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After that, an aliquot of 50 µL of every PCR product was analyzed on a 1.5% agarose gel using 
TAE; 1 mM EDTA. Later, the remaining PCR product was purified to remove excess of primers 
and dNTPs and the concentration of every purified PCR product was measured using a 
fluorometer. The PCR products were then combined in two different single tubes, each one 
containing either the IRL products or the IRR products. The PCR products were diluted in TE 
such that the final concentration of each PCR product was 200.000 molecules/mL and, shaked 
for 3-5 hours. After that, a final dilution that accounted for sample number (dilution of 1X for 
each unique barcode in the combined sample, IRR or IRL) was performed before submitting the 
samples for sequencing to the core facility. 
16.2. lllumina sequencing 
Isolated genomic DNA from tumors was quality-tested and quantified. After that, 2 µg of tumor 
genomic DNA was digested with NlaIII or AluI restriction enzymes. Then, IRR and IRL 
transposon-genomic junctions were ligated to adaptors that allowed the amplification of these 
fragments by PCR and digestion with BamHI-HF was performed to prevent amplification of 
transposons within the concatemer. These reactions, including the adaptor preparation, were 
carried out as described in the previous 16.1 section. The only difference in this process is that 
NlaIII and AluI make two cuts within the transposon and the genomic sequence, so four sets of 
samples were generated: NlaIII-IRL, NlaIII-IRR, AluI-IRR and AluI-IRL (Figure 26) 
Therefore, four primary PCR reactions were then performed using 2 µL of resulting DNA from 
the ligation reaction in order to amplify tranposon genomic junctions from right and left sides of 
the transposon. One was done using primers that annealed to the adaptor (linker primer long) 
and the left inverted repeat side (IRL) of the transposon and the other one included primers that 
annealed to the adaptor (linker primer long) and the right inverted repeat side of the transposon 
(IRR). The Taq polymerase and reagents were purchased from New England Biolabs. 
 
DNA 2 µL
HF Buffer 5x (includes Mg) 5 µL
dNTPs 10mM 1 µL
Linker primer long (10µM) 2,50 µL
IRR or IRL primer (10 µM) 2,50 µL
Phusion polymerase 0,5 µL
Water 31,50 µL
Reaction setup
 
 
Next, a secondary nested PCR was done using a primer that linked to the adaptors (linker-A2) 
and specific primers that included a 6bp-barcode for each sample that was used for sample 
tracking. 
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Diluted primary PCR DNA product (1:50) 2 µL
HF Buffer 5x (includes Mg) 20 µL
dNTPs 10mM 2 µL
Linker A2 primer (10µM) 2,50 µL
Barcoded IR-A1 primer 2,50 µL
Phusion polymerase 0,5 µL
Water 63 µL
Reaction setup
 
After that, 25 µL of each PCR product was run on a 1.5% agarose gel using TAE buffer and 
products were then purified to remove excess primers and dNTPs using the QIAGEN Minielute 
96 UF PCR purification kit (QIAGEN). Then, the concentration of purified products was 
measured using a Nanodrop spectrophotometer (ThermoScientific) and 25ng of each PCR 
product was pippetted into a sample pool with a final concentration of 25ng/µL. This final pool 
was then run on a single lane of a flow cell line on an Illumina Genome Analyzer IIx. 
 
PRIMERS SEQUENCE (5´-3)
IRR linker + GTAATACGACTCACTATAGGGCTCCGCTTAAGGGACCATG
IRR linker - Phos-GTCCCTTAAGCGGAC-C3-spacer
IRL linker + GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC
IRL linker - Phos-TAGTCCCTTAAGCGGAG-C3spacer
IRR GGATTAAATGTCAGGAATTGTGAAA
IRL AAATTTGTGGAGTAGTTGAAAAACGA
Linker primer long GTAATACGACTCACTATAGGGC
Linker-A2 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTAGGGCTCCGCTTAAGGGAC  
Figure 25. List of primers used in the adaptor and PCR reactions 
 
 
 
 
Figure 26.  Scheme representing LM PCR protocol to amplify transposon-genomic junctions 
from tumors induced by SB mutagenesis. Genomic DNA from every tumor is digested using 
AluI or NlaIII enzymes. Double stranded DNA adaptors are then ligated to the end of the 
genomic fragments. Then, a primary and secondary PCR (nested PCR) are done using specific 
barcoded primers that include the necessary sequences for directed sequencing on the 
Illumina GAIIx platform. Modified from Ref Dupuy (53) 
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17. CIS IDENTIFICATION  
17.1. Sequence reads analysis obtained from mammary gland tumors 
The sequencing output data was analyzed using the Integration Analysis System (IAS) 
developed by the University of Iowa Bioinformatics Department. For this analysis, two different 
files were used. The first one consisted on a FASTA file containing all the sequence reads and 
the second one was a barcode file containing the barcode sequence information of each tumor, 
the tumor ID (identifier) and the information that allows identifying which sequences were 
derived from the left inverted repeat (IRL) or from the right inverted repeat (IRR).  This barcode 
information was used to create individual tumor files including the information of the 
corresponding reads generated by sequencing. This process generated 4 independent files per 
tumor corresponding to the LM-PCR genomic fragments: NlaIII-IRL, NlaIII-IRR, AluI-IRR 
and Alu I-IRL. 
After that, barcode and adaptor sequences information were trimmed from every tumor sample, 
in order to be ready for mapping into the mouse genome. Resultant genomic sequences were 
then mapped into the reference mouse genome (NCBI37/mm9) using the Bowtie algorithm 
(103). The mapped genome sequences were then annotated and saved into a different annotation 
file for every tumor that contained the tumor ID, the gene name, the gene region hit (intron or 
exon), the predicted effect of the transposon insertion on gene expression (disruption or 
activation), the distance of the insertion from the gene, the location within the chromosome, the 
genomic address, the % of reads derived from the insertion site and the transposon orientation 
relative to the gene (same or opposite).  
Next, all transposon events that mapped to the donor chromosomes (chr1 from transgenic line 
6113 and chr 4 from transgenic line 6070) were removed from the data, to prevent any bias 
related to “local hopping” phenomena. Sequences that matched to the En2 or Foxf2 genes were 
also removed from the data, since sequences of these genes are contained within the transposon 
structure. Then, a clonality cutoff was calculated for every annotation file in order to remove 
non significant background insertion sites using statistical methods (27). This process is used to 
identify statistically significant clonal insertion sites that are consequence of the clonal nature of 
tumor cells, meaning that transposon insertions that caused driving mutations will be expected 
to be present in most of tumor cells.  Finally, these clonal insertion files identified from the four 
annotation files per sample generated after LM-PCR were combined in a new file for every 
tumor sample that contained a list of non-redundant insertion sites per tumor. 
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17.2. Monte Carlo simulation 
A modified Monte Carlo simulation was generated containing a set of randomly selected TA 
sites in the mouse genome for each transposon integration that was identified. Next, 1 x 106 
iterations of the simulation were performed. The output was used to define a common insertion 
site (CIS) region as the minimum genomic region in which N different insertions are observed 
to be significant when compared with the simulation (P = 0.0001). The CIS interval size was 
determined for CISs that contained between 3 and 10 insertions, and for which a single tumor 
contributes no more than 2 of the events.  
17.3. gCIS analysis 
The expected number of transposon insertion events was calculated based on the number of 
tumors analyzed, the number of insertion events within each tumor and the number of SB 
transposon target sites (TA dinucleotides) within each RefSeq transcription unit, including 10kb 
of promoter sequence. This analysis was performed using a chi-squared test that determined 
whether any RefSeq gene harbored more insertions than expected by chance. 
The statistic test was used to determine the p-value, with a single degree of freedom. After that, 
using the Bonferroni method, a statistical threshold of p = 2.63 x 10-6 correction was applied to 
correct for multiple hypothesis testing. Any remaining RefSeq genes that were not mutated in at 
least three independent tumors were also eliminated. 
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1. GENERATION OF TRANSGENIC MICE CARRYING THE 
CONSTRUCTION K5-SB11 
 
In order to obtain K5-SB11 transgenic mice, SB11 DNA was cloned into an expression vector 
that contained a 5.2 kbp fragment from the 5’-flaking region of the bovine keratin K5 gene, a β-
globin intron and poly adenylation signals (Figure 27) (143). After that, the K5-SB11 DNA 
fragment of 8.4 kbp was microinjected in B6D2 F2 mice embryos. Several transgenic founder 
mice were generated in the Transgenic Mice Core Facility of CIEMAT, and a transgenic line 
was established by breeding with B6D2 F1 mice. These mice were viable and fertile, and did 
not show any overt phenotype. 
 
Figure 27. Representation of the K5-SB11transgene.  
 
1.1. SB11 transposase expression follows the same pattern of keratin K5 
In order to characterize the expression pattern of SB11 in K5-SB11 transgenic mice, we used 
Northern blot, Western blot and immunohistochemical techniques. 
1.1.1. Analysis of transgene expression by Northern blot  
The expression of SB11 in K5-SB11 mice was tested by Northern blot assays of RNA isolated 
from skin of transgenic and control mice (non-transgenic littermates). A band of the expected 
size, recognized by a SB transposase specific probe, was found only in transgenic mice samples 
(Figure 28). These results indicate that SB11 is expressed in the skin of K5-SB11 transgenic 
mice  
 
Figure 28. Northern blot analysis of skin mRNA isolated from K5-SB11 transgenic mice (Tg) and 
control mice (Wt)  
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1.1.2. Analysis of SB11 transposase protein by Western blot 
With the aim of characterizing the expression pattern of the SB11 protein in K5-SB11 
transgenic mice we performed Western blot analyses of protein extracts from control and 
transgenic mice. We analyzed several tissues and organs that contain either stratified epithelia or 
cells that express keratin K5. 
Figure 29 shows high expression levels of SB11 protein in transgenic mice in tissues like foot 
sole, tail and back skin and considerable expression levels in palate, tongue, thymus and 
aglandular stomach (Figure 29 a-c), indicating that the expression pattern of SB11 in K5-SB11 
mice roughly paralleled that of keratin K5. 
 
Figure 29. Western blot analysis of SB11 expression in several tissues from K5-SB11 transgenic 
mice (Tg) and control mice (Wt) 
1.1.3. Immunohistochemical analysis of the SB11 transposase protein expression  
In order to assess the expression pattern of the SB11 protein in K5-SB11 transgenic mice at 
cellular level, we performed an immunohistochemical assay using an antibody against SB 
transposase in organs and tissues where K5 is expressed (in particular, those with stratified 
epithelia, in myoepithelial cells of exocrine glands and in thymus stromal cells). The SB11 
expression pattern was compared to the keratin K5 expression pattern by using an antibody 
specific for keratin K5. SB antibody staining was detected in most of the basal cells of stratified 
epithelia from back skin (Figure 30b), tail skin (Figure 30e), outer root sheath cells of hair 
follicles (Figure 30h),  
Results 
 67 
 
Figure 30. Immunohistochemical analysis of K5 and SB11 proteins. Histological sections from 
K5-SB11 transgenic (Tg) or control (Wt) mice were stained with K5 and SB antibodies, as 
indicated in back skin (a-c); tail skin (d-f); hair follicles (g-i); mammary gland (j, k) from a virgin 
female and prostate (l-n). The objectives used were: 20X (a- k) and 40X (l-n). Arrows indicate 
the K5 and SB11 expression in basal cells of the skin epithelia (a, b, d and e), outer root sheath 
of hair follicules (g and h), myoepthileial cells of mammary gland (j, k) and prostate (l, m) 
 
 
oesophagus, oral epithelium, tongue, palate and foot sole (not shown), and in myoepithelial cells 
of exocrine glands from mammary gland (Figure 30k) and prostate (Figure 30m), salivary 
glands, pancreas and in thymic stromal cells (not shown). SB antibody gave no staining when 
assayed in tissues from non transgenic mice (Figure, 30: c, f, i and n), proving the specificity 
of the antibody used. SB11 expression pattern was similar to that of keratin K5 (Figure 30:a, d, 
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g, j and l) with the exception that K5 showed a cytoplasmic location, as expected, while SB11 
was detected in the nucleus of the cells, due to the nuclear localization signal present in the 
transposases of the SB group. 
1.1.4. Immunofluorescence and IHC analysis of the SB11 transposase protein 
expression in the hair follicles. 
With the purpose of seeing if the SB11 was expressed in the epidermal stem cells, that are 
thought to be a cell population responsible of the origin of skin cancer among others, we 
decided to check if SB11 was expressed in the bulge region of the outer root sheath of the hair 
follicle, where these stem cells are located. Therefore, we used a CD34 antibody which is 
known to be a marker of the bulge stem cells (185) and a SB11 antibody. 
Our immunoflourescence analysis showed that as expected, SB11 was co-expressed with CD34 
in the immunofluorescence analysis in the bulge area of hair follicles (Figure 31). The same 
results were obtained by immunohistochemical analysis of the expression of CD34 and SB11 
proteins. 
 
 
Figure 31. IHC and IF analysis of SB11 and CD34 proteins. Histological sections from K5-SB11 
transgenic (Tg) mice were stained with SB11 and CD34 antibodies, as indicated in skin (a, b) 
and hair follicles (c). Asteriks indicate the SB11 and CD34 expression in cells from the bulge of 
the outer root sheat of hair follicules (a-c). The objectives used were: 20X (a-c) and 40X (l-n) 
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2. GENERATION OF DOUBLE TRANSGENIC MICE SB/T2 AND 
DETERMINATION OF TRANSPOSITION IN SKIN 
 
2.1. Generation of the cohort of SB/T2 double transgenic mice 
 
We wanted to obtain mice carrying transposons in their genome susceptible to be mobilized by 
the action of the SB11 transposase. With this aim, it was necessary to have the two transgenes 
(transposon and transposase) in the cells, so that transposons could be cut out from their original 
integration site, mobilized and pasted elsewhere in the genome of the cells expressing SB11 
transposase. With this idea in mind, we decided to breed K5-SB11 mice (named as SB) with 
two different lines of transgenic mice carrying a concatemer of T2Onc2 transposons (named as 
T2)(50). Both T2Onc2 transgenic lines differed in the original chromosomal localization of the 
transposon concatemer and in their copy number. It was estimated that line 6070 carries more 
than 200 copies located in chr4 and line 6113 carries around 350 copies in chr1(50). After 
breeding, we obtained a total number of 177 mice. As shown in Figure 32, all possible 
genotypes were obtained in these crosses. However, in line 6113, we found a decrease in the 
number of observed double transgenic mice in relation to the number expected (p = 0.033). This 
low proportion of SB/T2 double transgenic mice viable of the offspring was reported  
previously  in similar experiments expressing SB11 ubiquitously(50), and it has been attributed 
to lethality induced by SB transposition and/or DNA damage not repaired after SB excision. Its 
frequency varies among the different T2Onc2 lines.  
Figure 32.  Mice genotype distribution. A) T2Onc2 6070 line. Genotype distribution presented 
a χ2 value of 4.73 (p = 0.192). B) T2Onc2 6113 line. Genotype distribution presented a χ2 value 
of 8.71 (p = 0.033) denoting that offspring distribution in T2Onc2 6113 line did not adjust to 
mendelian proportions. 
2.2. Analysis of transposition events in SB/T2 double transgenic mice 
 
To study if transposon mobilization was taking place in the double transgenic mice containing 
both the SB11 transposase and the T2Onc2 transgenes, we followed two different approaches. 
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2.2.1. PCR analysis of transposition 
A PCR excision assay was done with the purpose of detecting transposition events within 
epidermal tissue of SB/T2 double transgenic mice. PCR analysis of the transposon array would 
result in a 2.2 kbp band in non-mobilized copies of the transposon and in a 225 bp band in case 
of transposition (Figure 33a, below). The band of 225 bp, due to its smaller size, is preferably 
amplified when transposition is taking place in only some of the copies, and usually prevents 
the simultaneous presence of the 2.2 kbp band. So, the presence of the 225bp band indicates that 
at least some transposon copies have been excised. We found that the 225 bp band was 
amplified in all the double transgenic mice analyzed by PCR analysis of tail DNA (for an 
example, see (Figure 33b), proving that transposition was occurring in double transgenic mice. 
However, this type of analysis does not give a quantitative estimation of the transposition rate in 
double transgenic SB/T2 mice. 
 
 
Figure 33. a) Primers amplify a 2.2 kbp product if a transposon has not been mobilized from 
the concatemer . If transposon excision occurs, a smaller band of 225bp is detected instead. b) 
Ethidium Bromide-stained agarose gel analysis of PCR products from tail tips DNAs of single 
and double Tg mice. The transgene(s) present in each mouse are indicated by + and - on the 
top. First and second lane corresponds to molecular weight markers. 
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2.2.2. Southern Blot analysis of transposition 
The previous PCR excision approach indicated that transposition was taking place in the tails of 
SB/T2 mice, but did not allow a precise quantification of the transposition rate in each sample. 
Therefore, we decided to perform a Southern Blot analysis of purer cellular populations, using 
DNA isolated from the epidermis and dermis of double transgenic mice SB/T2. 
Figure 34 shows how transposition can be detected by Southern Blot analysis. Bam HI sites are 
located within the plasmid sequences that flank each transposon in the concatemer and in the 
transposon itself. Digestion with Bam HI generates a 500 bp fragment that can be detected using 
a specific probe. When a copy of the transposon is excised from the concatemer and reintegrated 
into a new genomic location, Bam HI sites will not be flanking the transposon as in the 
concatemer. Consequently, it is expected that after transposition, BamHI fragments will have a 
different, variable and unknown size according to where the transposon copy integrates and 
where the nearest BamHI restriction site is placed. Therefore, we were able to recognize if 
excision of transposon copies from their original site has taken place because it will result in 
decreasing intensity (or even disappearance) of the 0.5 Kb band, and reinsertion into new sites 
in the genome may result in the detection of new very low intensity bands.  
 
 
Figure 34. BamHI digestion generates a band of 500bp, detected by a T2Onc2 probe when the 
transposons are located within the concatemer. Whenever the transposons are excised and 
reintegrated into a new position in the genome, the T2Onc2 probe detects BamH1 digestion 
fragments of unknown size. “B” stands for BamHI digestion sites. 
 
DNA was isolated from samples of skin epidermis and dermis from double SB/T2 transgenic 
mice (which carried both transposons and the SB11 transgene), and from T2 transgenic mice 
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that did not carry the SB11 transgene, as non-transposed control samples. A decrease in the 
intensity of the 500bp band was detected in samples from SB/T2 mice, indicating that some 
copies of the transposon have been mobilized. This decrease is clearly observed in lanes 1, 4, 5, 
7 and 10 in Figure 35, when compared to control samples (lanes 2, 3, 6, 8 and 9, with no 
transposition). Line 11 does not present the band of 500bp because it corresponds to a DNA 
sample from a non-transgenic mouse. This decrease of intensity in the 500bp band correlates, as 
expected, with the presence of a smear of DNA fragments of higher size that correspond to 
mobilized transposon copies when integrated into different parts of the genome (asterisks in 
Figure  35).  
Although transposition events should not occur in the dermis, some transposon mobilization is 
observed in dermis samples from double transgenic mice (see lanes 1 and 4). This could be 
explained considering that hair follicles remain in the dermis after epidermal separation. As 
outer root sheath cells from hair follicle express transposase (Figure 30b, 30e, 30h and 31c), it 
is not surprising that transposition is also detected in these samples. Figure 35 also suggests that 
the rate of transposition becomes higher with time, (from birth to adult mice), as there is a more 
pronounced decrease of intensity in the 500bp band in samples from older mice (compare lanes 
7 and 10,  that belong to the same animal at different ages). The quantification of this southern 
blot indicated that only around 10% of the transposon copies remained non-mobilized by the 
age of 8 weeks. So, we developed an animal model in which most of the hundreds of transposon 
copies were mobilized at the age of 8 weeks at least once. We next studied the mutagenic effects 
of this transposon mobilization in the development of skin cancer. 
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Figure 35. Southern Blot analysis of SB/T2 samples (+/+), T2 samples (+/-) and non-
transgenic sample (-/-). Thy-1 probe was used as a loading control.  “D” and “E” corresponds 
to DNA isolated from dermis and epidermis samples respectively. Asterisks mark samples with 
a visible DNA smear. P0, P12 (postnatal) and 8 weeks indicate mice age. 
 
3. EFFECT OF TRANSPOSON MOBILIZATION ON SKIN CANCER 
 
3.1. SB/T2 mice do not show spontaneous skin tumours  
 
These SB/T2 mice were viable, fertile and did not present phenotypical alterations, except for 
some alopecia and moderate lighter weight and smaller size. 
In previous experiments done with transgenic mice carrying the transposon T2Onc2 and an 
ubiquitously expressed SB11 transposase, double transgenic mice developed tumors, mainly of 
hematological origin (33). However, in our experiment, double transgenic SB/T2 mice did not 
develop more tumors than control mice at the age of 6 months despite the mutagenic effect of 
transposition. 
Therefore, we followed two different strategies with the purpose of minimizing the time of 
tumor development and maximizing the number of tumors obtained. The first approach 
consisted in the use of a well known two-stage chemical protocol for skin carcinogenesis, which 
is based on tumor initiation with the carcinogenic agent DMBA and promotion with TPA (44, 
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165, 215), administered as indicated in the materials and methods section. In addition, we 
performed a second approach based on the use of Tg.AC mice. These mice carry a transgene 
with an activated v-Ha-Ras oncogene, making them genetically predisposed to the formation of 
skin tumors. Therefore, these mice only need the application of a promoter agent, such as TPA, 
for skin tumor development. 
3.2. Carcinogenesis assays in SB/T2 transgenic mice  
 
Following the first strategy mentioned previously, DMBA and TPA were applied on nine mice 
with B6D2 hybrid background. Among them, five were SB/T2 and four of them lacked the 
SB11 transposase, thus acting as a control. 
The second approach was carried out using seven SB/T2 mice bearing also the Tg.AC transgene 
(named as SB/T2/Tg.AC) and five control T2/TgAC mice lacking the K5-SB11 transgene. 
These animals were treated only with TPA due to their Tg.AC background. Both lines of 
T2Onc2 transgenic mice (6070 and 6113) were used in the experiment. Genotypes and mice 
treatments are detailed in the Figure 36. 
 
Figure 36. Genotype distribution of transgenic mice used in the skin carcinogenesis experiment 
 
3.2.1. Tumor progression kinetics 
Tumor progression was followed after treatment with DMBA/TPA or TPA, depending on the 
genetic background, up to 42 weeks. Appearance of skin tumors was monitored weekly. If the 
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animals became moribund, they were euthanized and tumor samples were collected for 
histopathological and genetic studies. Interestingly, tumor developed sooner and with higher 
multiplicity in SB/T2/Tg.AC mice when compared to SB/T2 mice. As we can see in Figure 
37B, by 9 weeks, all SB/T2/Tg.AC mice had developed skin tumors and the number and size of 
the tumors increased with time and arised sooner than in Tg.AC mice without transposition 
(Figure 38B) 
 
 
 
Figure 37. Tumor-free survival plots. A) Kaplan-Meier tumor-free survival analysis of SB/T2 vs. 
T2 control mice. B) Kaplan-Meier tumor-free survival analysis of SB/T2/Tg.AC vs. T2/Tg.AC 
control mice. 
 
 
The average number of tumors per mice obtained was higher in mice with transposition 
(SB/T2/TgAC and SB/T2 mice) than in control groups that did not bear the transposase, 
(T2/Tg.Ac and T2, respectively) (Figure 38). Moreover, the latency period for tumor eruption 
was shorter compared to the control groups. In addition, papilloma regression phase occurred 
later in mice containing active transposons, starting between 22 and 24 weeks, than control 
mice, starting between 10 and 13 weeks (data shown in Supplementary Table 1).  
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Figure 38. Tumor-formation rate throughout carcinogenesis treatment. A) SB/T2 and T2 mice. 
B) SB/T2/TgAc and T2/Tg.Ac mice. Data is included only up to 26 weeks in A) and up to 8 weeks 
in B) because at that point we started to sacrifice animals due to tumor number and size.  
 
3.3. Histopathological characterization of the tumours 
 
A number of 38 tumors corresponding to SB/T2 and SB/T2/TgAc backgrounds were analyzed 
in order to identify relevant histological features when compared to tumors isolated from control 
animals T2/Tg.Ac and T2 that did not carry SB11 transposase. In order to perform a more 
comprehensive histological analysis, we incorporated tumours isolated from SB/T2 and 
SB/T2/TgAc mice that were not involved in the carcinogenesis protocol. These tumors did not 
present histopathological features different from those generated in treated animals of the 
corresponding genotype and have been included within their same genotype groups for analysis. 
(Figure 39) 
 
Genetic background Tumors
19 Papillomas (12 w/ basal proliferation)
7 SCC
SB/T2/Tg.AC 3 BCCs
(32 tumors) 2 Kerathoacanthomas
Transposition 1 Cervix Glandular Carcinoma
(38 tumors) 1 Keratoacanthoma
1 Mammary Tubular Carcinoma
SB/T2 1 SCC
(5 tumors) 1 BCC + SCC
1 Mammary Adenocarcinoma
T2 1 Papilloma
Control (5 tumors) 2 Sebaceous Adenomas
(10 tumors) 2 Hyperproliferation 
T2/Tg.AC 3 Papillomas (1 w/ basal proliferation)
(5 tumors) 1 Keratoacanthoma
1 Hiperkeratosis
 
Figure 39. Summary of tumor pathology analysis among the distinct genotype groups. 
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Most tumors corresponded to papillomas and were found mainly in back skin, but also in ear, 
eyelid and stomach. Despite the fact that we also found papillomas in control mice that did not 
bear the transposase SB11, tumors found in SB/T2 mice (both SB/T2/TgAC and SB/T2) 
presented a more malignant profile, characterized by basal cell proliferation and a tendency to 
invade the basal layers with infiltrating microcarcinoma foci. We also found several tumoral 
lesions that corresponded to SCCs (9) and BCCs (4), as well as 2 mammary gland carcinomas 
(Figure 39). In contrast, tumors obtained in control mice corresponded to benign papillomas 
and keratoacanthomas.  
 
As mentioned above, papillomas found in SB/T2 mice presented several histopathological 
characteristics indicating a more malignant nature, such as basal cell hyperplasia and 
pronounced basal cell atypia (Figure 40b, stars) and  microcarcinoma foci (Figure 40d, 
asterisk and 40e-f, arrows), accompanied with inflamation. Contrary to what happened in 
control animals (Figure 40a), SB/T2 mice also displayed BCCs with squamous differentiation 
(Figure 40g, arrows) and sebaceous differentiation foci represented by vacuolated clear 
cytoplasm of mature sebaceous cells (Figure 40k-l, arrows) and basal cell proliferation with 
atypia (Figure 40h, stars); and SCCs with infiltration of submucosa (Figure 40i, star) and 
accused atypia and anisokaryosis (Figure 40j, stars). All these alterations found in tumors in 
SB/T2 mice confirmed that they indeed exhibited a high tumorigenic potential that was not 
found in control mice tumors. 
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Figure 40. Hematoxylin and eosin stained histology sections from representative tumors in 
T2/Tg.AC (a) and SB/T2/Tg.AC mice (b–i) and SB/T2 mice (j-l). Squamous papilloma from 
control animal (a) and with basal proliferation (stars in b), basal cell atypia (stars in c) and 
microcarcinoma foci (arrows in d,-f). BCC samples presenting squamous differentiation (arrows 
in g) and sebaceous differentiation (arrows in k and l), anisokaryosis (asterisk in h), 
anisocytosis and atypia (star in h). SCC samples (i-j) with submucosa infiltration, anisokaryiosis 
(stars in j). l is a magnification of k. 
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4. ANALYSIS OF TRANSPOSON INSERTION SITES IN TUMORS 
GENERATED IN SB/T2 TRANSGENIC MICE 
 
4.1. Some tumors have novel transposon insertions clonally amplified  
 
A Southern Blot analysis of 20 tumour samples from 2 different mice (G196 and G391) and 2 
DNA control samples isolated from tail skin was done with the aim of studying the mobilization 
of T2Onc2 transposon in skin tumors from SB/T2/Tg.AC transgenic mice. We used a specific 
probe that is able to recognize the T2Onc2 transposon transgene both when mobilized and non-
mobilized from its original site in the concatemer (see Figure 34). Although some tumors 
present the same band pattern than non-tumoral DNA isolated from tail skin (Figure 41, lanes 
marked C and C26), in other tumor samples additional bands were present (for example, see red 
circles in Figure 41, lanes T12, T51 and T33,). These extra bands probably represent clonally 
amplified transposon insertions that are present in many of the tumoral cells, and thus could 
have been selected during tumor development. Theoretically, genes bearing these selected 
insertions are important in tumorigenesis.  
 
Figure 41. Southern Blot analysis of T2Onc2 integrations in tumor DNA isolated from “G196”, 
“G391” and “26” SB/T2 mice. “C” and C26 lanes correspond to isolated DNA from non tumoral 
tail skin samples. 
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4.2. Amplification of the transposon genomic DNA junctions 
 
After having confirmed that transposition and clonal amplification of some integrations are 
taking place in tumors that developed in SB/T2 mice, we tried to identify the transposon 
insertion sites within tumor genomes, with the purpose of identifying putative genes affected by 
the integration of transposon copies. With this aim, DNA was isolated from tumors to sequence 
the junctions between T2Onc2 transposon and mouse genomic DNA, and therefore, to 
determine the transposon insertion sites. 
Our initial approach consisted in PCR-amplification and shotgun cloning of the T2Onc2 
insertion sites. Cloned sequences were subsequently sequenced and mapped to the mouse 
genome to localize the transposon-mouse genome junctions that allowed the determination of 
the genes affected by transposon insertion.  
 
4.2.1. Shotgun cloning strategy 
Genomic DNA was isolated from 6 skin papillomas corresponding to 3 SB/T2/Tg.AC mice, 1 
SB/T2 mouse and from the skins of 2 control mice that did not carry active transposons. (Figure 
42) 
 
 
Figure 42. Summary of sequenced transposon insertion sites found in tumors from SB/T2 mice 
 
The DNA of each tumor was digested by restriction enzymes to split the left and right inverted 
repeats (IRL and IRR, respectively) of the transposon. These genomic fragments containing 
either the left or right part of the transposon were then amplified using a linker-mediated PCR 
modified protocol as described in Material and Methods. As a final result, we obtained a list of 
insertion sites from all tumours analyzed within the mouse genome. These results are 
summarized in Figure 43. In similar experiments performed in parallel using DNA of control 
mice without undergoing transposition, we did not obtain any insertion sites. 
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Figure 43. a) and b). Chromosome map distribultion of transposon insertion sites. The position 
of the insertions of each tumor is marked by a colour line next to the insertion ID. Each color 
corresponds to the tumor ID color in a) table. 
 
It is interesting to note that the rate of transposition near the transposon concatemer donor site 
(effect known as “local hopping”) is low, as we do not detect much more integrations in Chr 1 
or 4 than in the rest of the genome. This experiment confirmed that transposon mobilization was 
taking place within the tumors in animals containing transposon and transposase, supporting the 
results obtained in the Southern Blot analysis of the tumors shown in the previous paragraph. It 
also indicates the ability of the T2Onc2 transposon to move inside the genome, as transposon 
integrations were detected in all chromosomes (with the exception of the small Y chromosome). 
Another important data we found is that almost 75% of the sequenced insertions in the genome 
occurred in genes. This fact might indicate that these integrations in genes are being positively 
selected because they suppose a growth advantage to tumoral cells. 
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We did not find any CIS due to the limited number of sequences obtained using this approach, 
but this experiment confirmed that the transposon is able to integrate in any part of the genome 
and also that some insertions were clonally amplified . 
However, this approach presented substantial limitations, such as the significant cost and labor 
intensiveness that were required to create a big shotgun library that have all possible transposon 
insertion sites cloned. Considering these limitations, we decided to use a pyrosequencing 
approach as an alternative. This technology eliminates the need to clone DNA fragments and the 
subsequent amplification and purification of templates before traditional capillary sequencing. It 
also allows sequencing the greatest possible number of transposon insertions within the genome, 
making possible the identification of enough transposon insertion sites to characterize CIS 
among the tumors.  
4.2.2 Pyrosequencing 
Genomic DNA was isolated from 76 independent tumors from 20 double transgenic mice 
containing transposon and transposase (Figure 44, and detailed list in supplementary Table 2) 
 
Genotype and treatment Number of  
mice
Number of 
 tumors
SB/T2 (DMBA/TPA) 3 5
SB/T2/TgAC (TPA) 10 30
SB/T2/TgAC (none) 5 41
 
Figure 44. Summary of tumors used for DNA sequencing. Mice genotype and carcinogenic 
treatment are indicated 
 
Samples were prepared for pyrosequencing as described in Materials and Methods section. An 
aliquot of every secondary PCR product was analyzed by agarose gel electrophoresis to verify 
the quality of the sample before performing the pyrosequencing run. (Figure 45) 
 
Figure 45. Example of a set of tumour simples analyzed on gel electroforesis after BfaI 
digestion and subsequent LM-PCR. Products appear as a low molecular weight smear. Some 
samples have more abundant junction products of a specific size that appear as clear bands 
(see asterisks) 
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A pool of all the resulting mixed barcoded PCR products was then sequenced using a 454 GS 
FLX platform  
4.3. Common Insertion Sites (CIS) found within the genome allowed identification 
of skin cancer-related genes 
 
GS FLX sequencing data output consisted of two different files containing all the generated 
sequence reads from the 79 analyzed tumours. Each file corresponds either to the left or right 
inverted repeats reads (IRL and IRR) and some genomic DNA flanking the transposon insertion 
sites. We obtained a total number of 550589 reads from IRL side and 563865 reads from IRR 
side. The mean size of the reads was 100bp.  
Using the IAS (integration analysis system) software from the University of Iowa 
(http://ias.eng.uiowa.edu/IAS/), these sequence reads were analyzed to identify the 
transposon/linker sequences within the reads using BLAST and the flanking genomic insert was 
extracted into a separate file. After that, sequences were sorted by barcode identifier and the 
genomic junctions were mapped against the mouse genome (version mm9 of the database of the 
Genome Bioinformatics Group of the University of California Santa Cruz) using BLAT. 
Transposon integrations were aggregated for each tumor identifier (ID) and annotated based on 
the chromosome, base pair position and the number of sequence reads from the integration site. 
The UCSC genome annotation database was used to determine if integrations occurred within, 
or nearby a gene. If so, gene symbol, relative location within the gene, expected effect on the 
expression and orientation with respect to the gene were annotated. The orientation of the 
transposon in the insertion site reveals the presumed effect of the mutation over the expression 
of the gene (disrupted of promoted). 
After finishing this process, two annotation files were generated: the IRR file and the IRL file, 
containing 44120 and 67952 mapped sequences, respectively. After that, both files were merged 
on one worksheet, so that the independent reads generated from transposon IRL and IRR sides 
that matched the same transposon insertion site could be combined. After condensation, a set of 
108466 non redundant transposon integration sites from all tumors was generated, with tumors 
containing an average number of 1506 unique integration sites per tumor. Comparing the 
number of sequence reads and the number of mapped integration sites per tumor, we saw that in 
most tumors a large number of sequence reads resulted in a small number of integration sites 
(Figure 46). This can be explained by the fact that frequently sequenced sites represent clonally 
expanded transposon integration events in tumor cells that correspond to a small number of 
integration sites. 
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Figure 46. Comparison of the number of mapped sequence reads per tumor with the number 
of unique transposon insertion sites per tumor 
 
The integration sites in the donor chromosomes, chr1 in T2Onc2 line 6113 and chr4 in T2Onc2 
line 6070 were then removed to avoid false positive insertion events due to local hopping. 
Insertions corresponding to En2 and Foxf2 splice acceptors from the transposon were also 
removed, leaving a final number of 96768 non redundant insertion sites for subsequent clonal 
insertion sites analysis. A clonality score parameter for each integration site in each tumour was 
calculated considering the number of reads per insertion site and the number of reads at the top 
hit and a threshold value of 0.1 was applied to select the most significant clonal insertion events 
for subsequent CIS analysis. 
A modified Monte Carlo statistic tool and a gene-centric method (gCIS) were used to identify 
the CIS regions in the list of tumor insertion sites. Both methods assume that background 
mutations will happen at random throughout the genome and that causative mutations will 
cluster in regions within or near cancer genes. These regions (CISs) would have a higher 
mutation rate than expected by chance. The Monte Carlo method considers that transposons will 
be randomly distributed at TA dinucleotide sites throughout the genome and creates a simulated 
integration pattern that can be used to calculate the significance of any candidate CIS genomic 
region by determining the probability that transposon could integrate by chance within a DNA 
fragment of a given size. Parameters such as the number of TA sites in the genome, the number 
of insertion events per tumour and the number of tumours are used in this simulation to identify 
those loci with more integrations than expected by chance. The gCIS method specifically 
examined transcribed regions of the genome, avoiding the identification of CISs that were too 
small or too large to be biologically meaningful. 
Following this methodology, we finally obtained a list of 126 CIS (Figure 47). 
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Figure 47. List of the 126 CIS genes ordered first by the number of tumors that share a same 
CIS and then by its statistical relevance 
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5. FUNCTIONAL ANALYSIS 
 
Functional analysis of the 126 CIS list was done using the DAVID functional annotation tool 
(http://david.abcc.ncifcrf.gov/). The enriched Gene Ontology (GO) biological process terms 
obtained were related to transcriptional activity, cell proliferation, regulation of programmed 
cell death and epithelium development. Among GO molecular function terms, chromatin 
binding, transcription regulator activity and nucleotide binding were enriched. 
These results suggest that there is a positive selection in tumor cells for transposon integrations 
in genes that have a role in transcription and in gene proliferation, processes that are known to 
be deregulated in tumorigenesis. Moreover, GO Pathway analysis showed that several 
transposon-mutated genes are involved in well-known cancer pathways, like Wnt, p53 and 
Notch signalling pathways. In addition, a study of the protein domains present in the 
transposon-mutated genes showed enrichment in domains related to functions like protein 
kinase and serine/threonine protein kinases, also known to be altered in tumorigenesis (Figure 
48). 
The 126 CIS gene list obtained from mouse tumors was also confronted to the human genes 
listed in the human Cancer Gene Census (v15/03/2012). We found that 13 of the 126 genes 
(10%) had a homologue human gene (ATRX, BCL11A, CBLB, CDKN2A, CREBBP, ERBB2, 
KDM6A, PPARG, NOTCH1, NOTCH2, NSD1, PTEN and TP53), whose mutations have been 
catalogued to be causally implicated in cancer, so these data supports the idea that genes in the 
126 CIS list may have a role in human carcinogenesis. 
We also compared the 126 CIS to the human Catalogue Of Somatic Mutations in Cancer 
(COSMIC v59), that contains curated data from known cancer genes literature and systematic 
screens. In this analysis, we found that NOTCH1, CDKN2A,  and PTEN have been identified as 
somatically mutated in 48 %, 13.2 % and 5.1 %, respectively, of human  NMSC tumor samples, 
supporting the idea that genes in the CIS list might be important in human skin tumorigenesis. 
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Figure 48. GO annotation terms of the 126 CIS list. % refers to the percentage of the genes 
from the 126 CIS gene list that were significantly enriched in a specific GO category 
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5.1. Selection of 16 genes from the 126 CIS list for further analysis 
 
We selected for further study a list of 16 genes that were mutated in at least in 4 different mice 
tumors from more than one mouse (Figure 49).   
 
 
Figure 49. Genes from the 126 CIS list mutated in at least 4 different tumors. P-value refers to 
the significance of each gene contained in the original 126 CIS list. 
 
 
Despite the fact that we only found a few genes from the 126 CIS list that were somatically 
mutated in human skin cancer samples present in the COSMIC catalogue, we observed that 
somatic mutations in 15 out of this 16 gene list (Figure 50) have been detected in tumors 
originated in tissues other than skin.(Figure 50). Moreover, somatic mutations were found in 7 
genes out of the 16 gene list in human SCC samples: NOTCH1, NSD1, SYNCRYP, TP63, 
KIAA1267, PARD3 and TRPS1, strengthening the idea that these genes could be relevant in 
human skin carcinogenesis. 
 
 
Results 
 90 
Gene 
Symbol
Total 
Samples
 Mutations 
found
Skin 
samples
Mutations 
found in skin*
Tissue
Notch1 6044 760 117 15 663 hematopoietic/lymphoid, 32 SCC upper 
aerodigestive tract, 16 lung carcinoma (several 
types), 12 glioma, 14 breast carcinoma, 3 serous 
carcinoma ovary, 1 intestine adenocarcinoma,  2 
SCC oesophagus, 1 ductal carcinoma pancreas,15 
SCC non-melanoma skin
Nsd1 201 16 2 2 7 SCC upper aerodigestive tract, 2 serous 
carcinoma ovary,2 hematopoietic/lymphoid, 1 
lobular breast carcinoma, 1 kidney carcinoma, 2 
serous carcinoma ovary, 2 SCC non-melanoma skin, 
1 adenocarcinoma stomachCd44 219 1 6 0  pancreas
Syncrip 97 7 2 2 2 breast carcinoma, 2 serous ovary carcinoma, 2 
skin non- melanoma SCC, 1 serous carcinoma 
ovary, 1 SCC upper aerodigestive tract
NAA15 95 4 1 0 1 SCC upper aerodigestive tract, 1 serous 
carcinoma ovary, 1 malignant melanoma
Atp2a2 95 5 1 0 1 hematopoietic/lymphoma, 3 serous carcinoma 
ovary, 1 malignant melanoma
Wac 157 4 0 0 1 hematopoietic/lymphoma, 1 serous carcinoma 
ovary, 1 adenocarcinoma colon
Larp4b 93 4 0 0 1 breast carcinoma, 2 serous carcinoma ovary, 1 
astrocitoma
Tp63 417 16 8 1 1 breast carcinoma,6 SCC upper aerodigestive 
tract, 2 serous carcinoma ovary, 2 malignant 
melanoma skin, 4 adenocarcinoma lung, 1 SCC non-
melanoma
Fat1 47 25 0 0 9 SCC upper aerodigestive tract, 13 serous 
carcinoma ovary, 1 glioma, 1 pancreas, 1 
hematopoietic/lymphoma
Adam10 247 4 34 0 1 serous carcinoma ovary, 3 malignant melanoma
KIAA1267 76 7 3 1 1 ductal carcinoma, 1 hematopoietic/lymphatic, 1 
SCC upper aerodigestive tract, 1 
oligodendroglioma, 2 malignant melanoma, 1 skin 
SCC non-melanoma
Ankrd11 142 9 0 0 6 serous carcinoma ovary, 1 astrocytoma, 1 
adenocarcinoma colon, 1 adenocarcinoma 
stomach, 2 SCC upper aerodigestive tract
Pard3 99 6 1 1 2 breast carcinoma, 2 SCC upper aerodigestive 
tract, 1 serous carcinoma ovary, 1 SCC non-
melanoma skin
Tnrc6b 22 0 0 0
Trps1 224 11 9 3 1 breast ductal carcinoma, 3 serous carcinoma 
ovary, 1 ductal carcinoma pancreas, 1 nonsmall cell 
carcinoma lung, 1 clear cell carcinoma kidney, 2 
malignant melanoma, 3 SCC non-melanoma skin
 
Figure 50. Summary of somatic mutations found in the list of 16 genes selected from the 126 
CIS list using the COSMIC database for analysis (COSMIC v59). *Mutations in skin excluding 
melanomas 
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6. STUDY OF THE EXPRESSION OF SELECTED GENES IN A SET OF 
HUMAN SKIN TUMORS SUGGEST THAT THEY CAN HAVE A ROLE IN 
HUMAN SKIN TUMORIGENESIS. 
 
We then studied if mutations in any of these 16 genes are also important in the origin and 
development of human skin cancer. Our first approach consisted in the study of the expression 
levels of these genes in human skin cancer samples. We selected a reduced set of 11 genes for 
expression analysis because of its biological relevance in human skin carcinogenesis based on 
previous studies and also because the rest of the genes that were not selected for the study 
presented several technical drawbacks for gene and protein expression studies due to the large 
number of splicing forms or lack of available antibodies. Selected genes were NOTCH, PARD3, 
NSD1, WAC, TNRC6B, TRPS1, ATP2A2, FAT, ADAM10, SYNCRYP and TP63. A summary of 
the relevant biological features that link these genes to human skin cancer is presented below: 
 
-NOTCH1 encodes a transmembrane protein characterized for its role in development. Members 
of the Notch family belong to an evolutionary conserved signalling pathway implicated in 
different functions during embryogenesis and self-renewing of tissues. These functions include 
the maintenance of stem cells, cell fate specification, proliferation and apoptosis. Loss of 
Notch1 function has been correlated to development of BCCs and SCCs in mouse models of 
epidermal carcinogenesis (129), (139), and recently, mutations that disrupt this gene have been 
found in several forms of human SCCs(200), (1).  
-PARD3 encodes a protein that is involved in cell polarity and has been shown to be  
downregulated in colorectal tumour samples (116), in esophageal SCCs cell lines (216), and in 
ductal breast cancer samples (184). It is also somatically mutated in cutaneous SCCs (54). A 
non -functional PARD3 protein is related to a loss of polarized phenotype, epithelial cell 
hyperproliferation and acquisition of invasive potential (152).  
-NSD1 encodes a transcriptional regulator protein with H3K36 methyltransferase activity, being 
able to modify the activity of target genes. Nsd1 has been found to be altered in multiple 
myelomas, lung cancer, neuroblastomas and glioblastomas. Recently, somatic mutations have 
been found in some cases of skin SCCs (176). In addition, mutations in the NSD1 gene are 
associated with Sotos overgrowth syndrome, a dominant autosomal condition caused by loss-of-
function mutations or deletions and associated haploinsufficiency of the NSD1 gene. This 
disease is characterized by overgrowth and macrocephaly, together with an increased risk of 
tumorigenesis in several locations, including skin (59).  
-TRPS1 encodes a GATA transcription factor that has a critical role in tissue differentiation and 
has been involved in tricho-rhino-phalangeal syndrome. It is highly expressed in some ER (-) 
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ductal breast carcinomas and contributes to epithelial to mesenchymal  transiticion in breast 
cancer (175). 
-Mutations in the ATP2A2 gene are associated with a class of keratosis follicularis (Darier 
disease), an autosomal dominant skin disorder characterized by loss of adhesion between 
epidermal cells and abnormal keratinization.  
-FAT1 encodes a member of the cadherin superfamily that acts as a tumor suppressor, essential 
for controlling cell proliferation in Drosophila development. It also acts as a tumor suppressor in 
humans, being involved in cell morphogenesis and migration. Mutations in this gene have been 
seen in oral squamous carcinoma (OSCC), affecting cell adhesion, migration and invasion (130) 
-ADAM10 encodes a transmembrane metalloproteinase that is involved in the proteolytic 
processing of NOTCH1 in skin epidermis(203). Therefore, it plays a role in the Notch signalling 
pathway. It has also been found to be upregulated in invading peripheral tumor cells of BCCs 
(133) and to be important in prostate cancer, where it can be accumulated in the nuclei acting as 
a transcription factor (7).  
-TNRC6B plays a role in RNA-mediated gene silencing by both miRNAs and siRNAs. It is 
required for miRNA-dependent repression and siRNA dependent cleavage of complementary 
mRNAs by proteins of the argonaute family (106). At the moment, a role for this gene in cancer 
has not yet been established.  
-WAC is involved in histone H2B ubiquitinization, and regulates transcriptional activation of the 
CDKN1A gene, playing a role in cell cycle checkpoint activation (217) 
-The SYNCRYP gene encodes an hnRNP protein with RNA binding function involved in 
alternative splicing, polyadenilation and other aspects of mRNA metabolism and transport.  
-TP63 has a transcription factor function and plays an essential role in the development and 
maintenance of epithelial tissues. Mice lacking p63 present a profound block in the 
development of stratified epithelia and aplasia of multiple ectodermal appendages. A similar 
spectrum of phenotypic alterations is observed in human syndromes resulting from TP63 gene 
mutations (151).  
In summary, all this information supports the idea that these genes could have an important role 
in human skin carcinogenesis. Most of them genes have functions related to proliferation, cell 
morphogenesis, migration and cellular growth. So, mutation in these genes can lead to 
tumorigenesis. Based on this assumption, we decided to check the expression levels of these 11 
genes in human tumor samples to identify a possible relationship between tumoral 
transformation and their expression levels. 
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6.1. qRT-PCR analysis 
 
RNA was isolated from skin tumor samples and normal skin fragments adjacent to tumor areas. 
In total, we used 41 human skin tumors (30 BCCs and 11 SCCs.) and their paired control skins 
for analysis.  
Results showed that NOTCH1 expression was downregulated in most of the human skin cancer 
samples, both in BCCs and SCCs (see Figure 51). These results strengthen the significance of 
the data that were obtained in the transposon insertion analysis in murine tumors, where Notch1 
was the most frequently transposon-mutated gene. ADAM10, TNRC6B and SYNCRYP gene 
expression levels were frequently upregulated, while TP63 gene expression was found to be 
downregulated both in BCC and SCC tumor samples (Figure 51). 
We also found that some genes presented specific expression patterns associated to a certain 
type of tumour. For example, NSD1 and WAC gene expression levels were mainly 
downregulated in BCCs and SCCs, respectively; FAT1, ATP2A2 and TRPS1 gene expression 
was upregulated primarily in BCCs. Other genes presented different gene expression alterations 
depending on tumor type. An example is PARD3 which was often upregulated in BCCs but 
slightly downregulated in SCCs. This gene expression variability among tumor samples can be 
explained by intrinsic genetic differences inside each patient or within tumors, implying that not 
all tumors will have to be caused by alterations of the same pathways. 
Statistical analysis indicated that only the relative expression values of NSD1 and GLI2 (used as 
a positive control that is amplified only in BCC) were significantly different between the BCC 
and SCC groups (t-test, p-value <0.05). These results could be attributed in part to the limited 
number of SCC samples available for the experiment and to the variability in the samples 
previously remarked. 
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Figure 51. qRT-PCR analysis of the expression of selected genes from CIS list and GLI2 in 
human control skin and tumoral samples. a) Heat map indicating the relative expression 
(tumor relative to adjacent healthy skin) of the analyzed genes; b) and c) Box and Whiskers 
plot of the relative expression values in BCCs (b) and SCCs (c) 
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6.2. Immunohistochemical analysis of NSD1 and PARD3 shows a reduced staining 
in BCC human samples compared to control skin 
 
After proving that NSD1 was clearly downregulated in a set of 30 human BCCs when compared 
to their respective normal skin samples, we decided to study its expression at the protein level in 
both BCCs and SCCs samples.  
Therefore, we performed an immunohistochemical analysis to check the expression of NSD1 in 
a set of human skin control and tumor samples.  
In control samples, NSD1 protein was detected in most of the nuclei of basal and suprabasal 
skin keratinocytes, (Figure 52 a, b). We found that in 100% of the assayed BCC tumor samples 
(N=13) NSD1 staining was greatly diminished or absent when compared to normal skin. This 
difference in staining levels was more evident in samples where control and tumor areas 
appeared together (Figure 52, c, d).  
Immunohistochemical staining of SCCs samples revealed a diminished Nsd1 staining pattern in 
63 % of tumor samples (7 out of 11 samples) when compared to normal skin tissue (Figure 52e) 
and also more noticeable when compared normal skin and tumor areas within the same sample 
(Figure 52f).  
We also analyzed PARD3. Immunohistochemical staining of a total number of 7 BCCs samples 
using an antibody against PARD3 showed that cell membrane/cytoplasm PARD3 staining was 
decreased in 3 of the analyzed tumor samples (Figure 52h) compared to normal skin samples 
(Figure 52g), where PARD3 expression was present in the cell membrane/cytoplasm in most of 
the cell membrane/cytoplasm of basal and suprabasal skin cells. 
 
In summary, the selected 16 genes present different expression levels among the human tumor 
samples. However, NSD1 expression is clearly downregulated in BCC and SCCS tumors and 
immunohistochemistry analysis show that NSD1 expression is very low or absent in BCCs. On 
the other side, PARD3 mRNA is upregulated in BCCs and slightly downregulated in SCCs, 
while its protein levels are lowered in some human BCCs. Futher studies are necessary 
involving a greater number of samples are necessary to characterize how these proteins are 
affect skin tumor development. 
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Figure 52. Immunohistochemistry analysis of NSD1 and PARD3 expression in control skin and 
human skin tumor samples. (a, b): NSD1 expression (brown) is seen in nuclei in normal skin 
samples; (c, d): Comparison of NSD1 expression levels in normal skin (Ep) and tumor areas (Tu) 
in BCC samples. NSD1 staining is generally diminished within the nuclei of tumor areas (e and 
f). PARD3 staining in cell membrane/cytoplasm is shown in normal control skin in g). In tumor 
samples (h) PARD3 staining appears to be reduced when compared to healthy skin samples (g) 
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7. ANALYSIS OF TUMOR DEVELOPMENT IN HETEROZYGOUS P53 MICE 
CONTAINING ACTIVE TRANSPOSONS 
 
7.1. SB/T2/p53+/- mice developed more spontaneous mammary gland tumors  than 
p53+/- mice without transposition 
 
Since SB/T2 transgenic mice developed few spontaneous tumors, we decided to mate them with 
heterozygous p53+/- mice (FVB/J genetic background), prone to tumor development.  We used 
both 6070 and 6113 transgenic lines of SB/T2 mice. 
We found that SB/T2/p53+/- mice frequently suffered tumorigenesis in the mammary gland 
tissue. These mice also developed  tumors of hematopoietic origin, something that has already 
been described  in p53+/-  mice (45), (86). Although the number of tumors from hematopoietic 
tissues could be considered high enough to be considered for analysis, we decide not to include 
them in our study because several transposon-based studies have been already done (32), (53), 
(18), while a transposon-based carcinogenesis analysis  in mammary gland tissue has not yet 
been published. 
Therefore, we monitorized mammary gland tumor development in SB/T2/p53+/- females and in 
control p53+/- females lacking transposition. We observed that from the first mating, the 
offspring of SB/T2/p53+/- animals developed mammary gland tumors    with higher incidence 
than the control group formed by mice that were unable to undergo transposition (SB/p53+/-; 
T2/p53+/- and p53+/-). 41% of the SB/T2/p53+/- mice developed mammary gland tumors, 
while they were only found in 19.7% of the control animals. In addition, we saw that tumor 
development in SB/T2/p53+/- occurred after an average time of 49 weeks, while in control mice 
lacking transposition, this period increased up to 60 weeks. Statistically significant differences 
in mammary gland tumor-free survival were seen between experimental SB/T2/p53+/- and 
control group (p<0.0002). These results indicated that transposition facilitates the development 
of mammary gland tumors (Figure 53) 
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Figure 53. Kaplan-Meier analysis of mammary gland tumor free survival in SB/T2/p53+/- (n = 
66) and in control p53+/- mice (n = 71). Animals that died without tumors, that died of non-
mamary gland tumors or were alive at the end of the study were censored. Each censored 
animal is denoted by upward blips on the survival curves 
 
Mammary gland tumors appeared only occasionally in SB/T2/p53+/+ mice background. In our 
study, we obtained a total number of 5 mammary gland tumors in this genetic background. 
These tumors were included with those obtained in SB/T2/p53+/- for further analysis, including 
histopathological characterization and analysis of transposon insertions within the tumors. 
 
7.2. Histopathological characterization of the transposon/transposase mammary 
gland tumors revealed a common pattern of malignancy  
 
We collected 38 mammary gland tumors from 33 female mice. The histopathological analysis 
of the collected tumors revealed that all were mammary gland carcinomas which were classified 
as solid, tubular, alveolar, acinar or adenosquamous based on their histological features (Figure 
54 and Figure 55).  
Most of the tumors presented a highly malignant profile with different levels of differentiation 
characterized by frequent mitosis, anisokaryosis and degeneration areas (Figure 55, h, l, m), 
metaplasia (Figure 55m), keratin pearl formation (Figure 55f) and also displayed signs of 
inflammation (Figure 55l) and neutrophil infiltration (Figure 55k, asterisk).  
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# Tumors
Tubular 3
Alveolar 9
Tubular-alveolar 3
Carcinomas Papilar 1
Acinar 4
Adenosquamous 4
Solid 14
Total 38
Histopathological classficiation
 
Figure 54. Histopathological classification of the 38 mammary gland tumors isolated from 
SB/T2/p53+/- and SB/T2 mice 
 
7.3. SB11 expression in mammary gland tumors 
 
After characterizing the mammary gland tumors pathology in SB/T2/p53+/- and SB/T2 mice, 
we decided to check SB11 expression in tumor samples from SB/T2/p53+/- mice by 
immunohistochemistry and compare it with K5 expression in the same samples. Since SB11 
expression is controlled by regulatory sequences of K5 and K5 is only expressed in 
myoepithelial adult mammary gland cells, we wanted to see if the cell tumors were expressing 
the SB11 transposase. 
Results showed SB11 expression in mammary gland myoephitelial cells in normal tissue 
(Figure 56, a, b) being consistent with the endogenous keratin K5 expression in these cells, 
except for the location of the proteins, being K5 expressed in cytoplasm and SB11 in the nuclei 
of the cells. SB11 protein was also expressed in the nuclei of some tumor cells in SB/T2/p53+/- 
mice (Figure 56, d, f), presenting a similar expression pattern to that of keratin K5 when 
analyzed in the same samples (Figure 56, c, e). While K5 protein was expressed in mammary 
gland tumor tissues p53+/- control mice (Figure 56g), the SB11 antibody gave no nuclear 
staining in the same samples (Figure 56h), proving the specificity of the nuclear signals 
obtained in SB/T2/p53+/- mice. Both this result and the different incidence of mammary gland 
carcinogenesis previously described strongly suggest that SB transposition play a role in 
mammary gland tumorigenesis in SB/T2/p53+/- mice. 
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Figure 55. Hematoxolin and Eosin stained sections of a representative collection of mammary 
gland tumors showing the histopahological features of mammary gland tumors found in 
SB/T2/p53+/-(b-d) and (g-m); and SB/T2 mice (e and f). Stars mark regions of degeneration and 
anisokaryosis in (h, l, m). Asterisk marks region of inflammatory infiltrates in k. Arrows mark 
keratin pearl formations in f and degeneration areas in m 
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Figure 56. Immunohistochemistry analysis of K5 and SB11 expression in mammary gland 
healthy and tumor tissues. Histological sections from K5/SB/p53+/- mice (a-f) and p53+/- (g, h) 
were stained with K5 and SB11 antibodies (brown staining). All the photos correspond to a 20x 
microscope magnification 
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8. SEQUENCE ANALYSIS OF TRANSPOSON INSERTION SITES IN 
MAMMARY GLAND TUMORS 
 
8.1. Amplification of the transposon-genomic junctions 
 
Following the same experimental approach described for skin tumors, we next decided to 
analyze the transposon insertion sites in mammary tumors in order to identify genes mutated by 
transposon mobilization that may contribute to mammary gland carcinogenesis. 
Genomic DNAs were isolated from the 38 mammary gland tumors isolated and were processed 
for high throughput sequencing as described in the Materials and Methods section. In order to 
check the quality of the generated genomic products before submitting the samples to 
sequencing, every PCR product was run on an agarose gel. Correct samples appeared as a smear 
of DNA with maximum intensity between 150bp and 500bp (Figure 57). After that, all the 
samples were pooled and sequence on a single run on a GAIIx Illumina sequencing platform. 
 
 
Figure 57. Agarose gel electrophoresis of a set of PCR amplified genomic fragments obtained 
from mammary gland tumor samples 
 
8.2. Identification of CIS in the mammary gland tumors  
 
For CIS identification in mammary gland tumors, we used the improved method called gene-
centric CIS analysis (gCIS) that calculates the observed and expected number or insertion 
events within each RefSeq gene and assigns a p-value for each gene based on its statistical 
significance (27). For the analysis of CISs, we decided to divide the samples into two groups: 
one for tumors isolated from SB/T2 mice (n=5) and another one containing the tumors isolated 
from SB/T2/p53+/- mice (n = 33). This was done with the purpose of avoiding possible biases 
caused by the p53+/- background. 
After performing the gCIS analysis we obtained a list of 51 CISs related to a specific gene 
region within the genome in the tumors from SB/T2/p53+/- mice group (Figure 59) and a list of 
3 CISs from the tumors isolated from SB/T2 mice (Figure 58). An interesting result is that the 
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candidate cancer gene Rasa1, which was found at the top of both lists (Tables), is not dependent 
on the presence of a p53+/- background.  
Another interesting result is that in both gCISs lists (Figure 58 and 59) most of the genes were 
predicted to be disrupted by the action of transposon insertions. This effect can be attributed to 
the preference of the transposon we used, T2Onc2, which has a promoter that is weakly active 
for oncogene activation, so it mainly causes inactivation of tumor suppressor genes.   
 
 
Figure 58. List of 3 gCIS gene list obtained from 5 tumors obtained from SB/T2 mice ordered by 
p-value significance 
 
8.3. Candidate cancer genes in the gCIS list are enriched for signaling pathways 
and processes involved in carcinogenesis 
 
After obtaining the gCIS list, we used the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) program (80) (79) to identify enriched biological processes associated with 
these candidate cancer genes. 
The 51 genes were found to be associated with relevant Gene Ontology (GO) terms and 
statistically validated according to a p- value (0.01), determining the probability that each 
biological function assigned to the dataset was caused by chance alone. 
As it is represented in (Figure 60), organ development, gland development, transcription, gene 
expression and regulation of cell proliferation appeared as significantly enriched biological 
processes (BP) GO terms. Transcription factor, transcription activator, transcription regulator 
and nucleic acid binding were some of the most significantly enriched GO terms related to the 
molecular function (MF) category. And, in the cellular component (CC) category, the GO term 
nucleus appeared as one of the most relevant enriched terms.  
These results suggest that these genes might play a role in carcinogenesis, since relevant 
enriched biological processes and functions, like organ development, gene expression, 
regulation of cell proliferation, transcription activation and nucleic acid binding are well known 
to be altered in tumorigenesis (71). Moreover, the Wnt signaling pathway was significantly 
enriched when looking at KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways. This 
pathway has been related to tumorigenesis and specifically, to breast cancer (98), (77), (157), 
(122). 
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Figure 59. List of 51 gCIS gene list from 33 tumors obtained from SB/T2/p53+/- mice ordered 
first by number of tumors that share a same CIS and then by p-value significance 
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Figure 60. Gene ontology (GO) terms significantly over-represented in the 51gCIS gene list. 
Only terms with p-value < 0.01 are included 
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9. VALIDATION OF CANDIDATE CANCER GENES BY 
IMMUNOHISTOCHEMISTRY IN HUMAN MAMMARY GLAND TISSUES 
 
The final purpose of our study is to check if the candidate cancer genes that we have found in 
the SB/T2/p53+/- transgenic mouse model are relevant for human breast carcinogenesis. 
Although the list of gCIS is composed of 51 different genes, we have selected the two most 
representative genes at the top of the list for human validation because of several reasons. First, 
they were among the most frequently transposon-mutated genes in the gCIS list: Nf1, in 15 
tumors and Rasa1 in 11 tumors. Second, Rasa1 gene was also mutated in tumors originated in 
SB/T2 mice, so we can assume transposon insertions in this gene were not biased by the p53+/- 
genetic background. And third, it has not yet.been established a clear relationship between these 
genes and breast tumorigenesis  
 
9.1. NF1 and RASA1 as candidate cancer genes in human breast cancer 
 
 NF1 is a tumor suppressor gene that encodes the protein neurofibromin1, a negative regulator 
of the oncogenic Ras signal transduction pathway. Mutations in NF1 have been linked to 
Neurofibromatosis type I, an autosomal genetic disorder with an estimated birth incidence of 1 
in 2500(162).  
According to COSMIC, NF1 is somatically mutated mainly in soft tissues corresponding to 
neurofibromas and glomus tumors where 42.2% and 46.15%, respectively, of the analyzed 
samples were found to be mutated. NF1 is mutated in a variety of tumor tissues like lung, ovary, 
intestine, hematopoietic, skin, prostate and breast, among others (see Figure 61).  
 
Figure 61. Distribution of NF1 somatic mutations in different tumor tissues acording to 
COSMIC database (v60). 42.4% of the soft_tissue samples were neurofibromas, 46.15% were 
glomus tumor and 22.4% were nerve tumors 
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Although most of the somatic mutations correspond to nervous system tissue, there are some 
studies that have found an increased risk of breast cancer in patients diagnosed with 
neurofibromatosis, (56, 162). Moreover, neurofibromin1 is absent in the human breast cancer 
line MDA-MP-231(132). Taken together, all these results strengthen the idea that NF1 could 
have a role in mammary gland tumorigenesis.  
RASA1 encodes the RAS GTPase activating protein p120GAP (also named as RASA1), a 
member of the GTP-ase activating proteins (GAPs) family. RASA1 protein activates the 
GTPase activity of wild type RAS protein, shifting it into its inactive GDP-bound form, being 
significantly important in cellular proliferation and considered to have a tumor suppressor 
activity. After looking at COSMIC database, RASA1 appeared to be somatically mutated in a 
small number of tumors from skin, lung, ovary, prostate, upper aerodigestive tract and large 
intestine, being most of them classified as carcinomas. (Figure 62).  
 
Figure 62. Distribution of RASA1 somatic mutations in different tumor tissues according to 
COSMIC database (v60) 
 
However, somatic mutations of this gene have also been observed in BCCs (62) and the gene is 
located in a region of frequent LOH in BRCA1 mutant breast cancer (89). This type of cancer 
has gene expression profiles similar to triple negative breast cancer subtype (which also harbour 
activating mutations of KRAS and BRAF). So mutations in RASA1 could be associated to this 
breast cancer subtype.(78).  
9.2. Study of the expression levels of NF1 and RASA1 in breast cancer human 
samples 
 
As NF1 and RASA1 might have a role in human breast carcinogenesis, we decided to study the 
expression levels of NF1 and RASA1 proteins in human breast cancer and normal tissues by 
IHC, in order to check if their expression levels were reduced in human tumor samples  
As it is shown in the Figure 63, staining of RASA1 protein in cytoplasm was lower in 100% of 
the analyzed tumor samples (4/4) (Figure 63, b and c) when compared to human control 
samples (Figure 63a). Staining of NF1 protein in cytoplasm also appeared to be lower in 80% 
of the tumor samples (4/5) when compared to healthy samples (Figure 63, e and d), being these 
staining level differences more marked than in the staining for RASA1. Therefore, these results 
suggest that NF1 and RASA1 genes might play a role in human breast carcinogenesis.  
Results 
 108 
 
 
Figure 63. Immunohistochemical staining of human mammary gland tumors using antibodies 
that recognize NF1 and p120GAP proteins. a and d corresponds to healthy mammary gland 
tissue; b, c, e and f corresponds to tumorigenic areas from mammary gland carcinoma 
samples; d and e samples were isolated from the same patient. The arrows mark the NF1 and 
RASA1 cytoplasmic staining location 
 
In summary, we have identified a list of candidate cancer genes that can be important for 
mammary gland tumorigenesis. Among them, we have characterized the expression levels of 
NF1 and RASA1 in human control and tumor samples and we have observed that expression 
levels are reduced in human tumor samples. These results correlate with the transposon 
insertions pattern obtained in mice mammary gland tumors, since loss of function was the 
predicted effect.  
However, further studies are necessary in order to determine how a reduced expression of NF1 
and RASA1 is related to human breast carcinogenesis. 
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1. TRANSPOSON MEDIATED MUTAGENESIS IN EPIDERMAL CELLS 
PROMOTES SKIN TUMORIGENESIS 
 
In order to achieve transposon mobilization in the skin, we crossed transgenic mice carrying a 
SB11 transposase that was under the control of keratin K5 regulatory sequences to mice 
containing several copies of the T2/Onc2 mutagenic transposon.  
Results from SB11 expression pattern in SB transgenic mice reveals that this protein is 
expressed in cells from the basal layer of the epidermis and from the outer root sheath and bulge 
of the follicles. Recent experiments have suggested that some skin cancer types could arise from 
epidermal stem cells residing in the basal layer and the hair follicle bulge. Our results proved 
that SB11 was expressed in both types of cells. Therefore, this model allows transposition 
mobilization and subsequent mutation in skin stem cells. In addition, SB11 expression was also 
found in other epithelial tissues expressing keratin K5, such as thymus, palate, ovary, lungs and 
mammary gland. These results suggest that transposition could affect not only to skin, but also 
to other organs where K5 is expressed, and in fact we have also found tumors in some of these 
tissues, analysis of which is beyond the scope of this work.  
 
Our functional studies show that the SB transposition system works as expected. PCR and 
Southern Blot analysis (Figure 35) show that copies of the transposon T2Onc2 are mobilized by 
the SB11 transposase in the epidermis of the double transgenic SB/T2 mice. It is interesting that 
the transposition rate increases with time in the mice (Figure 35), considering that cancer 
develops through the sequential accumulation of mutations by normal cells. Therefore, this 
approach mimics this progression of the tumorigenesis process. However, only a few SB/T2 
mice developed spontaneous skin tumors, even though we proved that transposition was 
happening in the SB/T2 mice epidermis. There are some reasons that could explain this result. 
First, the mice used in the experiment have a background (B6D2) that is not particularly 
sensitive to skin tumor development (72), (206). Second, previous experiments using the SB 
transposon system have shown that it is necessary a latency period to allow accumulation of 
transposition events in the cells for tumor formation in certain tissue types(33). And finally, the 
MSCV 5’ LTR promoter used in the T2/Onc2, although active in keratinocites (11), is not 
specially strong. Subsequent experiments have proved that using a new transposon T2/Onc3, 
which contains the CAG promoter, which is expressed at high levels in epithelial cells, resulted 
in mice mostly developing a wide variety a carcinomas. However, this transposon was 
developed well after the beginning of our experiments, Therefore, in order to overcome these 
limitations, we performed the SB mutagenesis assay in mice of a Tg.AC genetic background, 
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more susceptible to skin tumor development or in B6D2 mice submitted to the well-established 
DMBA/TPA skin carcinogenesis protocol. 
 
Analysis of papilloma development in mice after treatment with carcinogens showed that mice 
containing active transposons developed a more papillomas, with a shorter latency period and 
less regression than control animals lacking the SB transposase enzyme. In addition, 
histopathological analysis of the tumors showed that control animals developed the typical 
benign papillomas and occasional keratoacanthomas that are normally obtained using the 
DMBA/TPA carcinogenesis protocol. By contrast, most papillomas obtained from SB/T2 mice 
presented malignant alterations, many of which were located in basal cells, where the 
transposase SB11 is expressed. Moreover, SB/T2 mice developed BCCs and malignant SCCs. 
Interestingly, BCCs are never seen in wild type mice and never arise as a result of DBMA/TPA 
treatments. These results show that mobilization of the T2Onc2 transposon in the basal layer of 
the skin increases papilloma formation and malignancy and is able to generate BCCs. 
 
Results obtained from Southern blot and sequencing analysis of a set of skin papillomas 
confirmed that new transposon insertions were clonally amplified in the tumors and that 75% of 
the sequenced insertion sites were located within genes in the genome. Several publications 
have proved that contrary to integrating retrovirus, the SB transposon does not present a 
significant preference for insertion near genes and instead, SB insertion sites are randomly 
distributed in the genome (113, 213). Based on this behavior, we can conclude that at least some 
of the transposon insertion sites in our mouse model are being positively selected during tumor 
formation because they confer a proliferative advantage to the tumor cells. 
 
2. ANALYSIS OF TRANSPOSON INTEGRATION SITES IN THE SB/T2 SKIN 
TUMORS ALLOWS THE IDENTIFICATION OF NMSC CANDIDATE GENES 
 
Pyrosequencing technology facilitates the use of transposons for cancer gene identification 
because it enables amplification and sequencing of tens of thousands of SB insertion sites from 
a mixture of tumors in a single sequencing run. In this work, we have identified a total number 
of 126 candidate cancer genes from a list of 108466 non redundant transposon insertion sites 
obtained from 75 skin tumors. Transposon insertion sites were also sequenced in the normal 
skin of two SB/T2 mice. Analysis of these insertions suggest that transposon mobilization is 
also happening in Wt skin but contrary to what happened in tumor samples, the number of 
insertions was very small and there was no positive selection over specific TA insertion sites. 
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The statistic tools to determine CIS regions from the transposon insertion sites mapped within 
the tumors assume that nondeleterous mutations will happen at random through the genome, but 
cancer driver mutations will cluster in these CIS regions that are characterized by having a 
higher mutation rate than expected by chance. We have obtained a total number of 126 CIS that 
encompass genes that might be important for skin tumorigenesis. Interestingly, no significant 
differences were seen in the genes mutated from Tg.AC TPA-treated and untreated or B6D2 
TPA-treated mice, indicating probably that mouse background or TPA treatment do no require 
different mutations in each case to develop tumors. Additionally, most of the CIS regions 
identified in our study were found in less than 4 tumors. This large number of CIS shared by 
only a few tumors could mean that there are different alternative combinations of mutations that 
may lead to skin tumors, and can also be explained by different grades of papilloma progression 
involving the mutation of different genes and the intrinsic genetic tumor variability.  
 
It is interesting to notice that our results present a low rate of local hopping transposition: 9.2% 
and 11% in T2/Onc2 lines 6070 and 6113 respectively, compared to what previous studies have 
obtained (95), (170), (171). This reduced local hopping rate can be attributed to the longer 
latency period of tumor development in the mice we used in our study. Since the transposase is 
expressing continuously, a long latency period for tumor development gives the transposon the 
chance to “hop” several times. Therefore, while many of the transposons will hop locally during 
the first rounds of transposition, many will hop to different chromosomes during the following 
rounds of transposition. In addition, the keratin K5 promoter drives high expression levels of 
SB11 transposase that could contribute to this effect. In fact, our analysis showed that double 
SB/T2 transgenic mice have mobilized at least once the majority of the copies of the transposon 
at the age of 8 weeks 
 
Looking at the orientation of the mapped insertion sites, we also observed that most of the genes 
that we have identified in our study are predicted to be tumor suppressor genes. These results 
are understandable since we used a promoter that has not a strong activity in keratinocytes. 
Therefore, it probably results in slight activation of the oncogenes in which the transposon 
inserts, with the consequence that positively selected transposon insertions are predominantly 
those in “antisense” which cause gene inactivation. By contrast, recent experiments using a 
different transposon that has a CAG promoter (which presents a strong activity in epithelial 
tissues) identified mostly oncogenes, being Zmiz1 the most frequently transposon-mutated gene 
(53). Interestingly, we have also identified Zmiz1 in our study in few tumors. Consequently, our 
study complements the results described by Dupuy (53) by identifying mostly tumor suppressor 
genes. 
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Our data shows that the Notch1 gene was by far the most frequently transposon-mutated locus. 
Three Notch paralogs (Notch1, 2 and 3) are expressed in the epidermis and Notch1 plays an 
important function in normal growth/differentiation control of keratinocytes (145). Numerous 
evidences link Notch1 to skin cancer. Reduction in Notch signaling within keratinocytes impairs 
their ability to execute the terminal differentiation program, resulting in formation of a defective 
skin-barrier and death if the areas involved are sufficiently large (21). It is been proposed that 
Notch1 mutation would prevent neoplastic cells from responding to differentiation signals in 
their immediate environment. Contrary to what happens in leukemia, where Notch1 acts as an 
oncogene, an opposite role for Notch1 is observed in skin keratinocytes, where it acts as a tumor 
suppressor. Loss of Notch1 in the epidermis causes development of mouse skin tumors that 
resemble BCCs and SCCs, in addition to inducing numerous papillomas (129), (139). It has 
been proprosed that deletion of Notch1 in murine epidermis increases susceptibility to 
DMBA/TPA induced skin papillomas and that loss of Notch1 in keratinocytes infected with a 
retrovirus transducing the Ras oncogene and injected into nude mice can form aggressive SCC 
while wild type cells do not (129). In addition, it has been suggested that Notch1 mutation can 
substitute for TPA in the chemical carcinogenesis protocol (41). Most of the tumors used in our 
study were isolated from mice with Tg.AC background which harbor a mutated H-ras transgene 
that is transcriptionally silent in keratinocytes, but is activated upon proliferative stimuli, such 
as the TPA treatment. According to the proposed mechanism by which loss of Notch1 activity 
may cause Ras-activation in skin cancer development and our data, mutation of Notch1 could 
provide the stimuli necessary to activate H-ras, even if there is no TPA treatment. However, as 
said before, we did not observe significant differences in the genes mutated in tumors in both 
populations of SB/T2/Tg.AC mice, treated or not treated with TPA. In addition, most of the 
genes we have identified do not seem to be regulated in expression arrays from TPA-treated 
skin or TPA-generated tumors (40), (81). 
 
It is interesting to mention that transposon mutations in the Trp53 gene were much less frequent 
than many other genes in the 126CIS list and were only found in 2 tumors. Mutations in P53 are 
frequent in human and murine skin tumors. However, most of these mutations are point 
mutations, in which a single nucleotide is substituted by another, and are located in “hotspot” 
areas, with a strong predominance in exons 5-8, which encode the DNA binding protein 
domain. The SB transposon mutagenesis mechanism is not well suited to produce point 
mutations. In addition, mutation of Trp53 in mice treated with DMBA/TPA is not seen until 
later phases of the treatment, when benign papillomas convert to SCC tumors. Therefore, given 
that our system can not cause the “typical” p53 mutations, mutations in other genes that were 
important for cells to become tumorigenic were selected instead, such as mutations in Notch1 or 
Nsd1 genes.  
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In our results, we neither observed significant transposon mutations in the PTCH1 gene, which 
is frequently mutated in human BCCs (63), (193), suggesting that there are alternative ways to 
develop this tumor in mice or perhaps there are other genes in this pathway whose mutation 
might also cause BCC. For instance, the CSNK1A1 gene, an inhibitor of the HH pathway, is 
among the CIS genes identified in BCCs, as well as several members of the Wnt pathway, that 
has been postulated to interact with or cross-regulate the HH pathway (179), (131). In addition, 
it has also been proved that NOTCH1 deficiency in skin and primary keratinocytes causes Gli2 
overexpression, leading to development of BCC-like tumors (129). Therefore, it is possible that 
the HH and Ras pathways interact in mouse skin (193).  
 
The final purpose of this study is to find out if the genes we have found using a SB mutagenesis 
approach in mice are important for human cancer. Contrary to what happens in tumors from 
DMBA/TPA treated mice, Ras mutations are infrequent in human NMSC. However, mutations 
in the NOTCH1 gene have been found in several forms of SCC (1), (176), (200). This was the 
most frequently transposon-mutated gene in our study and quantitative analysis of the NOTCH1 
gene expression in human BCCs and SCCs samples resulted in a strong down-regulation of the 
gene expression. Therefore, our study corroborates the importance of NOTCH1 in human skin 
cancer development. In addition, several other genes that have been identified in this study 
encode proteins involved in NOTCH1 regulation or function. For example, the ADAM10 gene 
encodes a protein that acts as a crucial protease in the cleavage of Notch1. It has been proved 
that epidermal loss of Adam10 results in impaired Notch processing in the epidermis and causes 
perinatal death and skin barrier defects in a knockout mouse model , pointing out an important 
role for Adam10 in skin differentiation (203). The results of our study show that the Adam10 
gene was mutated by the transposon, and 100% of the insertions disrupted the CDS. However, 
the QPCR results indicate that this gene was overexpressed in human tumor samples. In a recent 
study it has been seen that ADAM10 protein is clearly upregulated in human BCCs (133), 
confirming our results in human tumor samples. It is possible that mutations affecting the 
ADAM10 gene can create a non-functional version of the protein that will impair NOTCH1 
processing, but is still recognized by antibodies in skin tumor samples. Considering the roles 
that NOTCH1 and ADAM10 have in the skin epidermis, it is possible that tumors in mice arose 
as a consequence of lack of control of differentiation, and other transposon-tagged genes might 
be also negative regulators of differentiation, allowing the precancerous keratinocytes to 
proliferate and expand their mutations through tumorigenesis process. 
 
Another gene that was frequently transposon-mutated and has been related to NOTCH 
regulation is Trp63. It has been proved that a complex negative feedback loop exists between 
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NOTCH1 and TP63 that controls the balance between keratinoctye self-renewal and 
differentiation in human keratinocytes, being P63 expression suppressed when NOTCH1 is 
activated (128). Additional studies have found that TP63 gene is overexpressed in a variety of 
epithelial tumors including oral and squamous carcinomas (204). However, our results of QPCR 
consistently showed a downregulation of this gene in BCC and SCC human samples. Given that 
our QPCR does not discriminate between the several TP63 isoforms and that we did not check 
the tumors by immunofluorescence, we can not discard a change in the TP63 subunit 
composition in the human skin tumors. In addition, it is known that TP63 acts as a tumor 
suppressor in several tumors, such as prostate and bladder. 
 
The second most transposon-mutated gene in mice skin tumors was Nsd1, which mainly 
underwent disruption by transposon insertions. Results from the QPCR analysis from human 
samples agreed with the results obtained in the transposition experiment and revealed that NSD1 
expression was clearly downregulated in BCC samples. In addition, IHC showed that NSD1 
was absent or significantly reduced in 100% of the human BCCs samples analyzed, as 
compared to human control skin samples. In the case of human SCCs, 63% of samples 
presented reduced NSD1 expression levels. However, the QPCR analysis of NSD1 levels tested 
in SCCs samples did not present a clear downregulated expression pattern. This discrepancy can 
be attributed to the smaller number of SCC tumors used in the QPCR analysis and/or to the 
genetic intrinsic variability within the tumor samples. Nevertheless, these results suggest that 
reduced expression or loss of the NSD1 gene might be important for NMSC development. 
 
The NSD1 gene encodes a hystone methyltransferase protein that mainly demethylates histone 
H3-lysine36 (H3K36) (112, 140), acting as an epigenetic regulator. Several studies that have 
linked this gene to carcinogenesis support the hypothesis of NSD1 having a role in skin cancer 
development. First, Sotos patients, characterized by overgrowth features, present loss-of- 
function mutations (46) or haploinsufficiency in this gene (125) and have an increased risk for 
tumor development (181), including skin tumors(65). Second, chromosomic rearrarrangements 
of NSD1 have been linked to several forms of cancer including the childhood acute myeloid 
leukemia where the NSD1-NUP98 fusion gene promotes HOX gene activation (87, 195), (198) 
and genomic alterations of NSD1 have been also identified in breast cancer cell lines(220). And 
finally, several studies have linked the NSD1 functional status to different types of cancer: 
epigenetic inactivation of the NSD1 promoter through CpG island hypermethylation is 
important in neuroblastomas and glioblastomas (17), and reduced  mRNA and protein 
expression of NSD1 gene correlated with a decrease in proliferation and augmented apoptosis in 
myeloma cell lines after treatment with an antiproliferative compound (219) and changes in the 
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expression of NSD1 were found to be part of a “epigenetic gene signature” associated with 
prostate cancer progression(19).  
 
However, it is not clear how NSD1 loss of function can contribute to skin cancer tumorigenesis. 
Mice deficient in NSD1 exhibit an embryonic lethal phenotype with an enhanced apoptotic cell 
death in the ectoderm (146), implying that NSD1 is necessary for normal cell proliferation in 
mouse development. Additionally, it is known that the histone methyltransferase activity of 
NSD1 protein regulates transcriptional activation of adjacent target genes, such as MEIS1 and 
HOX genes (198), (17). In a recent study, it has been shown that NSD1 binds to the promoter 
region of more than 300 genes in HTCC116 colon cancer cells, including known cancer genes 
and cell-cycle regulators, and that NSD1 depletion leads to a reduced expression of target genes  
(117). It is remarkable that among the NSD1 target genes identified in these colon cells, several 
were specific or related to skin, including keratin genes. Moreover, it has been seen that NSD1 
physically interacts with ZMIZ4 and ZMIZ5 (202), two genes that belong to the same family 
than ZMIZ1, recently described to be involved in SCC tumor development using a SB-
mutagenesis approach (53). Even though no epigenetic-related genes have yet been linked to the 
development of skin cancer, the SETD2 gene, another H3K36 methyltransferase gene, is 
frequently mutated in renal carcinoma (39), (48). Supporting the idea that epigenetic 
modification could be causative in skin cancer, several of the transposon-tagged genes identified 
in this study have a role in epigenetics, such as the WAC gene, that binds to the RNA 
polymerase II complex regulating histone H2B ubiquitination, necessary for transcription(217). 
In addition, both  NSD1 and WAC genes were also identified as candidate cancer genes for 
colorectal cancer using the SB system (170), (171) and somatic mutations of NSD1 have been 
identified in head and neck SCC (176) and cutaneous SCC (54).  
 
Pard3 was the third most mutated gene by transposon insertions in papillomas and the analysis 
of the transposon orientation pattern within the tumors revealed a preferential loss of function 
effect. However, results from the QPCR analysis showed that PARD3 expression was clearly 
upregulated in BCC tumors, while in SCC was slightly downregulated. But 
immunohistochemical results revealed that expression of PARD3 was diminished in more than 
half of the BCC tumor samples analyzed compared with normal skin samples. As it happened 
with ADAM10 gene, it is possible that a non-functional protein is being overexpressed in human 
BCC tumors.  
 
The PARD3 gene encodes a protein expressed in the cytoplasm that interacts with other PAR 
family members affecting asymmetrical cell division and apical polarized cell growth. Epithelial 
cells have asymmetric distribution of cytoplasmic and membrane proteins to regulate cell 
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structure and transduce signals. Both tissue polarity and cell polarity are lost early during the 
neoplastic process due to alteration in polarity genes expression and/or their protein subcellular 
localization (109). Deletion of PARD3 in tumor cells may disrupt cell polarity and adhesion and 
some studies have supported this theory. Copy number loss of the PARD3 gene was observed in 
15% of primary esophageal squamous carcinoma cell lines and its expression was significantly 
reduced in  tumors and correlated with aggressive tumor phenotypes (216). In another study, a 
significant low expression of PARD3 was seen in the distal margin of rectal cancer samples 
(116). Furthermore, inactivating mutations in both alleles of PARD3 have been reported to 
occur in prostate cancer cells (96).  
 
In addition, it has been proposed that alterations in the expression or functional activity of cell 
polarity proteins may prompt stem cells to divide symmetrically and to evade differentiation, 
providing a cancer stem cell-like environment (138). Stem cells undergo asymmetrical divisions 
by reorienting their mitotic spindles to generate a differentiated cell and in mammals, the 
dynamic interaction of PARD3 with a protein complex is key for the regulation of spindle 
orientation and cell differentiation (127). Therefore, loss in PARD3 expression could contribute 
to skin carcinogenesis by deregulation of asymmetrical cell division in the epidermal tissue. 
Moreover, in order to reorientate the mitotic spindle, cells respond to extracellular signals 
during which Notch signaling has a major role and it has  been proved that reduction of the 
levels of some of these ligands result in the impairment of Notch signaling (190).  
In conclusion, in this study we have identified several genes that are mutated in the transposon-
generated tumor experiments and are presumably responsible for the development of these 
tumors. The analysis of the predicted role of these genes will allows us to infer that the 
processes are altered in skin tumors, including epigenetics. 
 
3. TRANSPOSON MOBILIZATION PROMOTES MAMMARY GLAND 
TUMOR DEVELOPMENT IN HETEROZYGOUS P53 MICE 
 
Although heterozygous p53 mice only develop a few mammary gland tumors, mostly due to an 
early death from sarcomas and lymphomas (45), it is known that P53 is important for breast 
cancer development. A high proportion of patients with Li-Fraumeni syndrome carry germ-line 
mutations in the p53 gene that predispose them to a high risk of developing breast cancer, 
among others. Consistent with this information, it has been shown that approximately, 20% of 
all breast cancer cases present somatic mutations in p53 (155) and are most frequently found in 
the ductal carcinoma in situ (DCIS) stage (92). 
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Our results show that p53+/- mice carrying active transposons in keratin K5-positive cells 
developed mostly mammary gland carcinomas and these tumors arose earlier and with a 
statistically significant higher frequency than in control mice that did not undergo transposition,. 
In addition, we also found some mammary gland tumors in SB/T2/p53+/- animals. These results 
suggest that transposition in keratin k5-positive cells contribute to mammary gland tumor 
development.  
 
In this study we have proved that the SB11 transposase is expressed in the myoephitelial cells of 
the adult mammary gland, following the same expression pattern of the keratin K5, except (as 
expected) for the nuclear localization of the SB11 protein. In addition, we have observed that 
SB11 is also expressed in mammary gland tumors from SB/T2/p53+/- mice. It is believed that 
most of the mammary gland tumors originate from mammary gland epithelial cells that in the 
adult mouse do not express K5. However, recent theories point out to the relevant contribution 
of mammary cancer stem cells in tumor development (3). This theory supports the idea that 
breast cancers are initiated and maintained by a subpopulation of tumor cells with stem cell 
features, known as cancer stem cells, characterized by self-renewal, differentiation and 
extensive capacity for proliferation properties. In the mouse, the existence of adult mammary 
gland stem cells was demonstrated by showing that a functional mammary gland could be 
generated in immunodeficient mice by transplantation of a single cell with stem cell like 
properties (161), (174). These mammary stem cells would be able to originate mammary gland 
cell lineages, luminal and myoepithelial cells and it is thought that these progenitor stem cells 
could be K5 positive (174), (221). Therefore, in our study, it is possible that transposition events 
took place in mammary gland stem cells that expressed K5 and consequently the SB11 
transposase, originating tumors that are traditionally considered to arise from non-K5-
expressing cells.  
 
4. ANALISIS OF CIS IN THE SB/T2/P53+/- TUMORS LEADS TO 
IDENTIFICATION OF BREAST CANCER-CANDIDATE GENES 
 
Recent advances in breast cancer genome sequencing have found driver mutations in 40 cancer 
genes and in 73 different combinations of mutated cancer genes among 100 breast tumors, 
highlighting the complexity of this genetic heterogeneous disease (173). Insertional mutagenesis 
using the SB transposon could allow distinguishing driving mutations from a large number of 
accompanying passenger mutations that do not contribute to cancer development. 
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In this study, after high throughput sequencing of 38 mammary gland tumors from mice 
undergoing active transposition we have obtained 51 candidate cancer genes. From the five 
SB/T2 mammary gland tumor samples we only identified 3 CIS. However, it is remarkable that 
one of the cancer gene candidates, Map4k5, showed up only in this mouse background, 
indicating that probably it participated in a pathway alternative to p53 for the development of 
cancer. The other two genes, Trps1 and Rasa1, are present in both CIS lists from mice with and 
without p53+/- background, suggesting that the transposition insertions within these genes are 
not biased by the mouse genetic background (although Trps1 does not pass the statistical test in 
the group of p53+/- mice, it is also mutated in several tumors in this group). As it happened with 
the papilloma CIS list, based on the data of the orientation of the transposon with respect to the 
orientation of the mutated gene, most of the genes we identified were predicted to have a tumor 
suppressor function.  
 
The results from the bioinformatics analysis on the DAVID platform revealed that the set of 51 
candidate cancer genes was enriched in ontology categories related to transcriptional activation, 
regulation of cell proliferation and several cancer pathways. These data strongly support the 
idea of a positive selection in mammary gland tumors for transposon insertions in genes that are 
important for tumorigenesis. Among the enriched cancer pathways, it is interesting to mention 
the Wnt signaling pathway, which is known to be deregulated in breast cancer. The candidate 
cancer genes Axin1, Lrp5, Ccnd3, Vangl1, Creebp and Smad3 were found to be significantly 
enriched for this pathway and AXIN1 and CCND3 were among the most mutated genes by 
transposon insertions.  
Transgenic expression of b-catenin in the mammary gland leads to tumor formation(97). In 
human breast cancer the levels of this protein are increased  and it has been shown that elevated 
transcriptional activity of the b-catenin gene contributes to the development of the disease (76). 
The AXIN1 protein functions as a negative regulator of the Wnt signaling pathway by being 
involved in the phosphorylation of b-catenin, which leads to ubiquitination and proteolysis of 
the protein. Therefore, a selection for transposon insertions that disrupt the Axin1 gene with a 
loss-of-function effect will be a way to increase the levels of b-catenin that can lead to 
mammary gland tumorigenesis. Moreover, a recent work has related the loss of function of 
AXIN1 to breast cancer since its lost caused overexpression of MYC oncogene in human breast 
cancer lines (14). The Lrp5 gene also belongs to the Wnt signaling pathway and was also 
mutated by transposon insertions. This gene encodes a protein that acts as a correceptor with 
FRIZZLED protein to transduce signals by Wnt proteins, resulting in accumulation of an 
activated b-catenin. Recent studies have established a relationship between a non-functional 
LRP5 receptor and mammary gland tumor development (20). In addition, the VANGL1 gene 
encodes a planar cell polarity protein that acts as a Wnt signaling protein and recent experiments 
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have shown that increased levels of VANGL1 transcripts correlates with risk of breast cancer 
relapse (5). 
Although most of the genes were disrupted by transposon insertions with opposite orientation in 
relation to the targeted gene, CCND3 gene was one exception, carrying transposon integrations 
in its same transcriptional orientation. This fact suggests that CCND3 acts as an oncogene in 
mammary gland cancer. This gene encodes the Cyclin D3 protein, which is required for cell 
cycle G1/S transition. Our data agrees with the current scientific knowledge since this gene has 
been found to be overexpressed in human breast cancer cell lines (218), leading to an 
acceleration of cell cycle progression  and subsequent increment in the cell proliferation rate 
that is associated with mammary gland tumor development. 
Another of the most transposon-mutated genes was Pten and was found to be disrupted by 
transposon insertions. This tumor suppressor gene encodes a lipid phosphatase that 
dephosporylates PIP3, antagonizing the PI3K/AKT pathway. Deletion of PTEN results in 
increased activation of the PI3K/AKT pathway that leads to elevated cellular levels of PIP3 
mimicking the effect of PI3K activation.and triggering the activation of its downstream 
effectors, PDK1, AKT/PKB and RAC1/CDC42. AKT activation stimulates cell cycle 
progression, survival, metabolism and migration (37), (47). Somatic mutations of PTEN are 
seen in only 6% of breast cancer samples (COSMIC), but LOH of PTEN is frequent in sporadic 
breast carcinoma (163) and 37% of breast tumors analyzed in a recent study presented no 
detectable or reduced levels of the protein (136). In addition, several mouse models have 
suggested that decreased Pten expression leads to an increased risk of breast tumor formation 
(111), (156). Therefore, our results are in agreement with the role of PTEN in mammary gland 
carcinogenesis and corroborate that in our study tumor cells selected CIS that were important 
for mammary gland tumor development. 
 
The relevance of these candidate cancer genes identified in mammary gland tumors to human 
cancers was also tested by comparing the list of 53 genes with the list of human cancer genes 
contained in the Cancer Gene Census catalogue 
(http://www.sanger.ac.uk/genetics/CGP/Census). The results showed that 11 of the genes (21%) 
had a human orthologue in the catalogue (NF1, NFIB, CCND3, PTEN, TOP1, GATA3, 
ANKHD1, ANKRD11, SETD2, CREBBP and FBXW7). Therefore, they are recognized as human 
cancer genes. Furthermore, an analysis of the 53 genes using the COSMIC database (COSMIC 
v60) revealed that 52% of the genes were somatically mutated in breast carcinoma tumor 
samples and 4 of them were among the Top 20 most mutated genes (PTEN, GATA3, CHD1 and 
SETD2), supporting the relevance of these genes for human breast cancer. In addition, several 
genes among the list of Cancer Gene Census that were not previously related to human breast 
cancer, have been identified to carry somatic driver mutations in a recent high throughput 
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sequencing study that involved 100 tumor samples (173), including NF1. Moreover, in a similar 
high throughput sequencing study involving more than 50 samples, another transposon-tagged 
gene (RUNX1), not previously observed in clinical breast cancer samples, has been recently 
found to be significantly mutated in breast cancer samples (13) and also correlated with 
oestrogen-receptor positive cancers (57). 
 
We decided to focus our attention on the NF1 and RASA1 genes for further functional studies 
and validation in human breast cancer samples for several reasons. First, Nf1 and Rasa1 were 
the most mutated genes by transposon insertions in the 51 gCIS list. Second, Rasa1 has not been 
previously correlated to breast cancer, and although Nf1loss has been recently identified in an 
oncogenomis approach in mammary gland (196), when these experiments were performed that 
was not known. And finally, the Rasa1 candidate cancer gene was identified as a CIS regardless 
of the mouse genetic background. 
Our IHC results show that NF1 and RASA1 protein levels are significantly decreased in tumor 
samples compared to normal breast tissue protein immunostaining and consequently, these 
results agree with the positive selection of transposon insertions that disrupted the CDS of these 
genes in mammary gland tumors of SB/T2/p53+/- mice. Therefore, a loss of function of these 
predicted tumor suppressor genes could be important for human breast cancer development.  
Even though a clear functional relationship between mutations in these genes and human breast 
cancer has not yet been established, some studies have pointed out relevant data that support 
this hypothesis. First, the Neurofibromatosis I disorder is linked to loss-of-function germline 
mutations in the NF1 gene. This genetic autosomal disorder is characterized by the development 
of tumors from nervous tissue origin and some studies have reported an increase of breast 
cancer risk among neurofibromatosis female patients (162), (201). And second, as it has been 
mentioned previously, cancer high throughput sequencing studies have identified somatic 
intragenic mutations in this gene in clinical breast cancer samples (173).  
The NF1 gene encodes a GTPase protein that acts as a negative regulation of the RAS 
oncogene, driving it into its inactive GDP-bound form. Therefore, a non-functional NF1 protein 
could turn on constitutive activation of RAS, resulting in an increase of cell proliferation, 
characteristic of tumorigenesis. The RASA1 gene encodes another GTPase protein that also acts 
as a suppressor of RAS function. Since activating RAS mutations are rare in human breast 
cancer, but the RAS protein is very often overexpressed in the tumors (55), our results suggest 
that transposon mutations in Rasa1 and Nf1 genes were selected because their disruption can 
lead to RAS constitutive activation and thus to an increase in cell proliferation rate. Moreover, 
results from the immunostaining analysis of NF1 and RASA1 proteins in human samples also 
indicate a reduced expression of these proteins in tumor samples and very recently, frequent 
mutations in NF1 have been identified in human breast carcinomas (196).   
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Further analysis to find out how NF1, RASA1 and more candidate cancer genes identified by 
transposon insertions correlate with human breast tumor molecular profiles will be interesting, 
considering that breast cancer molecular subgroups have different tumor outcomes and 
prognosis. For example, the NFIB gene has been identified as a potential target for ER- human 
breast cancers (124). The TEAD1 gene, that encodes for a transcription factor, has been 
correlated with poor clinical outcome in prostate cancer (100) and theTRPS1 gene encodes a 
GATA transcription factor associated with ER- ductal carcinomas (175).  
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CONCLUSIONS 
 
1. K5-SB11 transgenic mice express the SB11 transposase in basal cells of the  epidermis 
and other stratified epithelia, in cells of the bulge region of the hair follicle (where some 
skin cancers are thought to originate from), and in myoepithelial cells of exocrine 
glands. So, this transgenic line can be used for mutagenesis studies in these cell types. 
 
2. Double transgenic mice carrying K5-SB11 transgene and an integrated transgene array 
of T2/Onc2 mutagenic transposon (SB/T2 mice) undergo efficient transposon 
mobilization in the skin. 
 
3. SB/T2 animals treated with TPA, either in wild-type or in H-ras mutated backgrounds, 
developed more malignant tumors of the skin and with decreased latency than control 
mice that did not undergo transposition. SB/T2 animals also developed basal cell 
carcinomas. 
 
4. Analysis of the transposon insertion sites in the skin tumors identified 126 genes that 
were frequently mutated in different tumor samples and thus may have a role in human 
skin cancer development. Notch1 was the gene more frequently mutated. 
 
5. Some of the most mutated genes in murine tumors also presented an altered expression 
pattern in human skin tumor samples. The expression level of NSD1 was decreased in 
most of the human skin tumor samples analyzed, compared to control samples. 
 
6. SB/T2/p53+/- mice developed mammary gland tumors with higher incidence and with a 
shorter latency than mice that did not contain active transposons.  
 
7. Analysis of transposon insertion sites in the mammary gland tumors from SB/T2/p53+/- 
mice identified 53 candidate genes that might be relevant for breast cancer development 
 
8. Two of the genes of this list (NF1 and RASA1) were found to be downregulated in 
human breast cancer samples, indicating that mutation in these genes could be 
important for the development of this pathology 
  126 
Conclusiones 
 127 
CONCLUSIONES 
1. Los ratones transgénicos K5-SB11 expresan transposasa en las células basales de la 
epidermis de la piel y otros epitelios estratificados, en las células de la vaina radicular 
externa, donde se cree que algunos tumores de piel se originan, y en células 
mioepiteliales de glándulas exocrinas. Por tanto, estos animales pueden ser usados para 
estudios de mutagénesis en estos tipos celulares. 
 
2. En ratones dobles transgénicos portadores del transgén K5-SB11 y el concatémero de 
transposones mutagénicos T2/Onc2 (ratones SB/T2), se da una movilización de los 
transposones de manera eficaz. 
 
3. Los animales SB/T2  sometidos a tratamientos de carcinogénesis de piel, tanto en fondo 
silvestre como portadores de un transgén H-ras activado, desarrollan tumores de piel 
más malignos con un menor período de latencia que animales sin transposición. Los 
animales SB/T2 también desarrollan carcinomas basocelulares. 
 
4. El análisis de los sitios de integración del transposón en los tumores de piel identificó 
126 genes  mutados frecuentemente  en diferentes  tumores y que  pueden por tanto 
tener un papel importante en el desarrollo de cáncer de piel. Notch1 fue el gen más 
frecuentemente mutado. 
 
5. Algunos de los genes  más mutados en los tumores de ratón  tenían un patrón de 
expresión alterado en muestras humanas de tumores de piel. En concreto, NSD1  se 
expresa a menor nivel en las muestras tumorales humanas que en muestras control. 
 
6. Los ratones SB/T2/p53+/- desarrollaron tumores de glándula mamaria con mayor 
incidencia y con un período de latencia más corto que los ratones que no contenían 
transposones activos. 
 
7. El análisis de los sitios de inserción de los transposones en los tumores de glándula 
mamaria de los ratones SB/T2p53+/-  identificó 53 genes que pueden ser importantes 
para el desarrollo de cáncer de mama. 
 
8. Dos de los genes de esta lista (NF1 y RASA1) estaban reprimidos en muestras humanas 
de cáncer de mama, indicando que mutaciones en estos genes podrían ser importantes 
para el desarrollo de la patología. 
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